var title_f42_23_43376="Extravasation of circulating leukocytes";
var content_f42_23_43376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Schematic representation showing extravasation of circulating leukocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Physiologic mechanisms which underlie hematopoietic cell movement into extravascular tissue. A sequential multistep process, which involves margination, rolling, adherence, and diapedesis, is utilized by circulating leukocytes to migrate out of the vasculature and move directionally into areas of inflammation and infection. Each discrete step requires the actions of different adhesion molecules. Selectins primarily mediate cellular margination and rolling, while integrins and their receptors (immunoglobulin superfamily of adhesion molecules) are used for adherence to and diapedesis through endothelial cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43376=[""].join("\n");
var outline_f42_23_43376=null;
var title_f42_23_43377="Ulcerative colitis CT";
var content_f42_23_43377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of ulcerative colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5iPAOeuOPpQVwgbGASfxpcZHTDccY6/SgHgcnOc596ABeDyOe9AGCDg46Zp2SOOgzyKOB9elADUGQcDPPSj+9+QBNSIqkDOSRxj8f8/lTMAk5H8+9AAceb3OfTmm4PGT+tP4DZ649OlG3CjqCOeO1AEbKRQBkGn7crxySfSlJXJyMgjI57UAM2nBODxS9N3p0xupSAB8wbPTntSnJBwxOfzoAjwQo9DzT1A2jP8uc0q9iOvt3/GnAHI4JH060AMbGRxmlxxz8xFG3gEBjn2pxXCk/hgUAMA5UjGO+P/r00jnAHOPWpFU9sDtik5AyM+/FAEZHfGBml4z609hzzn1wabgAnoePpQAnAIAxj1zTT0wex9aUdO5xRn8u9ACY4IHHPc0o4HPymlyMHrk880Adcj8xQAnT+XWjG7PHPtTlXcvQcGgrliDk0AKSCDjOT3/xpoPTntzSkZJABGOxpdmSOO3P1oAYDz2oBwacRj8++RTtuMjnHse9ADACcYGe9JnHHv3p6qdxz6c57U3bgAnPqfpQAHpgDPvSfMFP07UHrxnFKcd88D34oAZj5enfk0Hqc5z704r0Hp65o45A3Y9qAECnOegHP0pCpxmn56+350YzjI49aAGY4yBxSkEDj055pxxlsAgehpG4xgdqAGjrzzSuQcYAGBg470nI4IwaD+ZoAXB3ev0pVXIJyBjnmkI57/Q03ODmgBaDnB9KOp470YJ4wSaAEPWg9PxpzjDYPUUlAARmg4oxzgUpUnkAn6UASHOc5yBzzSp93p3wT2o+g49RS+4HU9cf5zQAhAGeBSrycdOMCnxhix2ZY8/dBP8AKtCDRdTnYCOwueSQC0e0D8TQBmxn5fx/Lj/61NbhunHpnNdBD4V1h2G+COEZxulmX+h61OvhG9JHmXVkq+xZv0x/hQBzGcdQaG47j867D/hEURlMmp84/gtyffqTUw8K6fGBuurx9oJOxVHPtQBxXVehx1pMEE5zk+3f1rvrbwzprKrLb3MrE/N51wFwPwFJJp2g24bFispU7f8AWO3PXHWgDg+QcZ28cbuMigEYJyPpgH9K722W1aYxw6LAsIH+sMO7B+p69asRak0OI7LRZN6sV/1SoMetAHncaGViArknptUmryabfMQBYXZ/3YW6flXYz3HiK5P7qAW49FI5NaNtoviC5WJprqT/AIAuc+x7UAcKmgarIMrYTr6b8If1NOPhzVuptVXp96ZAf516bJ4Nu2gDXFwFjXku5BP1NWYPh/bpuZ3ikkPILrn/APVTsB5YPDt9uKs1mrY+606805fDd4RzPYe/+kD/ADivYY/CcEefNnUN/wBM4gTU0PhWwLLIwYMvAygBNFgPFF0C4aTb9o09nY5A+0DJ9ulH/CN34OB9mOeBi4Xk17ovhfTtwH73Ax6D/Ipf+Ec07cf3DEnpnsfrRYDwZvDuokEmOBiB/wA9l5pP+Ea1UY/0Rc+nmp/jXu7+G7fklfujpjqfrUcfhy0SQglwSOpAosB4V/wj2pjIFsv/AH9Q/wBacvh7VTkraH/gMin+te3x+HrV53dlLDPGQOalHhnTmK/udrZ5xgZNFgPCDoOqBgPsE+RwMAH+tRvo+pLnNhc5HXEZP8q94l8J2j5CPsOfTP0xVS68HpJho7pQTztGVH4gUWA8LksruNl821nTJ43RMOahdGjOGVl7YII/mK9rHg+5gfdBctJ6r5rAAfQ1Qu/DGtbiYLq54Hy7gjqD+IzRYDyEAEn5hxTlUcEfp/LFelapoepsoFxZ2UkijndZ7d34g8VgT6Q6pmTR49wGD5MrKf50gOTA3EDAyTgUnQg45roDYWAdVnTULRmHIYB1H6ZxQ3h8MxEF5vbPSSBgB+PI/OgDnyCAc9x371H0AwR6/Stt/D2ohiIY4pD/ANM5B/WqFzY3Vtkz2syDB5ZCB19elAFQHmkznOTTiATxgD16UbDzQAme5zg0hxT2AA+Xrnue1JjAOemcZx9aAGn03Hn3zThjdnjHemnPP+TSjPGM4oAawwOc8djSDGP8af1xjgfSmMu3Hf3oATHpzT0+Xv6dDSjA6Dg9vzpUHIU9qAG8dcd6b/EalK5kBxkZ96jcEY65xnpQAnPU9+aKMAHk9qQHHuPSgBxJHFISW6n2obrzySKHOTnj/CgDs7XwhEuw3t4Sx6pCvT/gR/wrQj0vT7Pakdik0mOC4Mmfr2FdZZafp1phljDNJlixJyW/zmr0UHllGcDcCCBjimBzFrY38u1IJBbrj5UhQDHr2rZGnXyIymLI65Zsk1twygbsLtbOeB2rTtHLYG7ccDpx+FAjjJNOnQbpiid+tRLErKAs4LY9a7S7tYp08t1C5O7IFchq0UlkJTBBmROF4xn/AD/WgAe3BRkCkoxwfkzn9KWCyOQACgHyjisF/Emp2rgFSi8FR0I9f8MU1fEckxRUEgznPbacf5/WgZ1Is7UHM0p4ON3AqbGjxKMqTwSSOlc7aXjzArLEyH+6e9XY4owvIKk85NAE0t7awn9zal2BJA65rL1O/wBQKiSxtVAc5YP29gKrXHirSLZyiiS5bpmJeBj0NZ9341zGsdnZYx0aY4wfoP8AGgC3Za94gMwVbUMMddu3r711Gj6vqKAfa7eVecnbIGU/Qj+org7LxhcrMPttvGYz1MIKkD6E812NheWt5YLNBcqYT1JbAH19KAOmXxLYllEkrQMONr9D7Vaj1eCVC6TpjJyc8AelcLfatotqD9onhkckDYjb/wBB2qhNqWhKiTJIhYnAEWcj3I9B70XEenLe+Zny2Kg5GVPzY9v/AK9TLeNkFl2g4yrcn615tDeaY8ohttQUyMQVUS53H29fpUF3q+p6fc7Aw2fwszckUXA9RW7YkHbwR1FOe8ILtM21FA69BXndpe6lOiSecwGPvg8flVlILibcZLh5WJySTTuB1t74htLS3DCUO3ZYssRXnvibxtrV4zx6fC1naA9TGS7Hv9BXS2OjqWOeFxkjnOaW80j92G2ADPAJ/nSAt+FvE0eq6ZHlVW4QbXQ+o681sDUPuKcHPevLtXvrexn+zxgxyFRuZOij1qLTb/XXQCyuY5MnG6RcFR9KLgeuJeZOcLkjO7tQ16qKyqvIOfSvLZNR1C2ZXv8AXrWFl6rtBJH0zVaTxJZF97apdyAfwiIgfyp3A9Xa+jDZIbOOcECov7RjyNowehGa8mn8XWit+4ivJMcfNhQ365qFvFqtt/4l8xGMjdLgYpXA9li1CPbxnC/xdc0yQ2twQJkRwR12c59jXkEXjBYwdtrcr6YfpWxoXiN9TlaKFpoZUG7Yecj1zRcD0RrHT7lT50Mag9SowayL3wpayc28zDKlSTwfpxWet/eKhHmEjsSORVOfUNSk8vfIUAf94F5JHtQBSvPB19DJI8GoO64I2sA3/wCsVQl0nV7WEqsinYRsGCPwycioPEGp6pb6rstbydYyittOOPbpzUmneKtUspAl3ueNhkMRgk+56e1AxkonZH+36SkoVd2QFY++M96ZaaPpGpIS1r9nfbjaSVPsQOh+tdfbeIbG6iRrmKKNnIXZIPmJq+bPTrxcpkFhg+W2cGgDzSXwpbuxENzLGF/ichhnP4VnXXhmZWKWtzHMo7EbT/WvUZ9ICo3ktlecBhWO+nSREmEQLnsBjOfXHWiwHms+lXcRYGLKgj7rZHtVWS3ljz5kTAY4OO9enPZzNlJYY3UtzhsnA7e9QTaPaxRs8UEpcg5UEnFIDzLHGB1J7GgqCcnr35rtJ9LE0zbrKbgj5mAAx7Y7Vn3ugqkZZFkU5PA/IZ/WgDm+QeRkmnRnkeh4yauT6fIhYICQMZBGD/nrVYRlGKsjD69qAG9TjtnimP8AN689Pc1OowwPzZLc49ahfPJz9aAGMMMBikOeelP79+eBjv7VcvbIW0NrNFcLLFOrOCqsu0g4IORQBR4x3z7U0jGOKeRtz1XGKGHPC57d6APVNM1f7RILZ42aVgGGVAxg9PqK6xZEljAf5cj5fTH+NZsnh2D/AFyOwmUkiRSQenelF21vABcqcJjk0xGtEhaN3jcn+8K09ISZmdNmWAGABVHwXZXPirWV0zSIiZJPmd2BCxoMAu3oBkD3PFfTfhjwfpPh60WK2gWabHzzSjczHv8ATvQB4RLZSBTsB2jnJHIrP1CwinUeYMlhnLDkH/PFes/EOwt4NSXygYiVEg2DaBnIxn8M/jXntzFHnax3Hkkd/rTA8o8U2tsYyXZQqn5uOfTr61xcDmKVGiOPTOOee/tnFeyazoqz7nhYOTkNGeBXBaho/wBmkV41xgk7SMj9PcCkxj9PupJiSybXH4g/Q0zxNbXd7pTxWeS5xuUdWHpxVKKeS0gSTCKT8rYOQQenPpg/56Vp6dfC4VyDu29+h59uw9qAPNpIXgdo5o3iZeCrKQc/5/lTDjkjnPTt/ntXtM1kl1DloFlDc4kUGsLUvBVnfRGSyb7HKzY+TJRv+A9vwosB5qoyeSB9anV2e3NuSfKL+YV7E/nWpqnhvVNMch7ZpohjEsA3L+XUfyrJRlcgcZJzg8EUgHL8g+XA7YxjJz0p+Dg5I7575pVweeD16Hil+9k57dSR0xQAwgnlSAy4xjt/hXdDU9L1S2gjV0E5jAdG659OetcRvA53AdCOea2vDmjXup6pbm3t5VhjYSPKwKqB6A9yaAOwto1WEBFG1MKMVr6VAs0+G37ejYHWmTadMvzZVR3JPSt7wtZMGVt27np2piNO2tAFVEQAg9O/51Ff27eQWCAopJ3tnH0FdVFZqgyfL3d88ilmTe4UMrHBLMPT6UwPnDxjpkp8SbYY3LTKB04znHNN8TRS6NoNraRTtG0jhWwMFhjJ57V6BrFmY/EcmFcAfMPTHtXnHxGS4GtxtIri02ARMfu57+wNIZyaqq5KgD9OPSl457AcfSl59j37ilUHORjAI5zSAANxxnANPLEsu8jA46Dp9KMcknOSevOaco6ZHbgZ5NADTnnntj/Of61d0jUZdMuzcQxRuxG3DccfWqxGQOBt680AYHpjv2/GgDfu/F9/cQmOBY7bPDMBuZR7Vp+BZtRvTcebK01uh2BmGTu78/THWuMAAK5HA9uBivUfh/avb+HLViwR5iZOPQnIpgRanpMVyFRzIjEZJTr9DntXP22nGK8kgYtLZsgCuxyMg9uf14rr9ZvUtiilwN+UDjrzXOzOBciFEbDKT8zdT64oAz9RksUkMYnH7s5CkZAOOOfWrdtemG3zFKUAK9Tyc/yrn9rZcOSCCQxYE810elusmlJ5qhFGVz3wOM/WkAsviKRFCvOofH3SpbNPh1Oa4I2pC4Zsb0PQY5471RuNNkkkl8sxrjkAd8+vpWnomiSqVZyVcjgE8UwL8VrcSMNpIyRjHU//AFq1bexnYAOQoJ5J7CtLTNNIDeY3OM4rTaBSUYcAYxu5OPWmIwn06CQjLswAwxHAFZ11pduEZghIPU9zXUzxmOF3wMkksG6j/Cueu2klbkkr2A9KQHMSaDYNIC8Zj5J+Unmql94eaNC6x+fCcfKB8wA6Yrqb2E/ZZNi5IHHocf41zs2tywTeZcDagjG2FTlifw6CgZzl/oIVPNtJBnPMJHTHb/P/ANauduEZHZJAVYcYJz/npXfafdXd9qMT3ELQRKrEkqRnPTjv0q5rXh2HU7dmj2pJnKuOoz2PrSA8wzwORn2FaepArpGkg4z5cvf/AKaGql/azWlw0VwpV1J69D7itLXJVm0zRCkEMGy3kUiIn5iJn+Y5JOT0444HvQBjZ9x+dbnjHwvc+GDon2yeGX+1dLg1SLysnZHLnarZ/iG3msIArnswrtviVr2m+Jv+EVawndDpugWmmzrNGRiWIMG24zleRg0AerxIRuHG1hj05rJ1yJJVESAh8/M3pjrWgXV1A3ZPGFxg4rE1GdxcuEYhlUlRnIJxVCPpT4IeEo/Dvhk3s0eNQ1HErkrgpGPuIPbq31au3066uJy/mxALvI4PKexqHwpdx3/hjSLqFlMc1pE42nI5QVpKyea6qQH7jvUjMLxfpSX1g0wXMsa4OO69/wAuv515FqWnOk2FAIJ7Hmvfa8/8Z6J9naSeCBXgf5uOCDz8vH6U0I8rljO5d44JAG4d/TNYer6dFcRhY49r7if8a62/iy+Yvlyd2DWbJgNjhgDkDPPvTA8r1HTBHcI8acO/IJwp554/z1rTbQ180yooSUjGPUV039n29/NdMhYSQfPjPc0sDxSxho5I3G4hs8FT6f4UgM7TAxsirEBkPIJwfpSaugsYTdWrNGsxDMvUZ9sewq9dRtC0dzDGQhPzA/N+NRXMiz25icgxsMBVBHNMChb3TTkkFFZeFXGOKgv7CK5ldZYIWBXP7yIHmia2NpLHLEd0QALbuePwq55oeXLBMHoynr6UgOel8OWBCs1pAr/7CfKT7UsPh7TPl32UGM/xjkH61uuMMTtdVIxkc01NrANgjjgYzigDPh0u1tjmC1iiU9WRBmtCCQIgVXk567uFH4VIqofuMm4c45qxDbveZMSHCD5ip4z6UAUZpCZGLEPH9Oa6DwowWFdrOCW+76ikg0NpVy7+XkZ2kcVHbwXGkOSgLxKcllOCPpTA9Alhj+zIqyBMHJDZyxP86rCOR3beFVQOJs8D/Z9c9/pSaVcreWSM2WQcsCMmnSBFbI2orDknoPrQBw/iqDbqCSrhy4xuU5HHrXGeN0Fz4ZvI2jAdFEqnuCvNdv4pwxBiYArk5Rs5HsK5157aeDMmGVhhlxk0gPEeSgO3OfmBpxQZ6Ywe/ORW/wCKNDXTJvOtA/2CRuQefKP19DWGMbc5HPJOen1pDFUYJ+U+mT/jTu2DkLj/APXVyw027vy/2WEsOzE7VP51or4Y1IsNwgBxxl/0oAxUG7PHLdaI0LyIqRs0jnCovVj7V0cHhK9dws08UZ77Mmux0TQbPSlV0UPcMADIeWI9Pb8KAOW0bwVcyyQyas0UVr1aJGy59FPt9K7m4khgt+MBI1AC9AMe1P1C6htYgzKEbr8zdBWZe24mtGadvkccoeuKYjm9c1CK5vraPasm1w5bdgZ9P603U70RNBcWzqyspBKrwfbJqCZRbXJjgUC4lIG7aSSvYAdjj0rTv9OjsdKhiZJW2DKfLk5NAyhLCl80bhlUjG9MHLcfrS3lvMIYIreLDI4yucE+57GrUVtKn2RzDKDjDDP+ryPbithLdXkCqjkj3wKAK+n6exd9u1d74Gz9c12enWEkKYdWcbRjKkAn2PtxUOnWBU7liVQcAHPJx/nrW4u4Nnc25QFz0yfWmIkhtSq4ZCzAAEE10vhzwxJrN0iRquwZOR91V7GsrS4jNcqAGAU53H2r2rwTphstLWeVNk1woJBHIXtn3OSfxHpQwPLfG/w41azs/P0mFdQLMFZIh84Hrg9vpXmGsaPe6IAup2dzbyMeFcEfma+w6zPEOh2Ov6ZPY6lCJIZVwT0I9CDSuM+NCrXalclYiMFh61Bp+mR2bNHbRAgjDSucscepNdHqmmjSNQvLN2RpLaVoxg4AGetVOTFhSu5+gH+fxoEUpICmdgBboCeT/wDqpluoSECQEfMcgH730q/MjABWclhg4zgenaoJYVVSxZVYDgD170AYPijTbK90ya6uXWLyRkS/88+eOnXnFcZ4m0+5sNO0KK7gkhka1kkAkUqSpuJACAe3H8672aGNGMFwgmt5PlkQjg89/esbxDYS6vHp0bTMwispxE8zliii+lUDJJOAAfzoGeeFQP5c8V6V8OPBfhPxFoc934k8S32lXiXDRJBb6bLcqY9qkMWVSAcsRj2HrXnd5BJay+VKMMp6jv7j9a63wf43j8N6ZJZvpZvGeUyl/tHl4+VVxjaf7uc+9ID0hnbPKBlBzn0rOmjRr3MauQAdw71oTlEjDh1BxgBl5asuWbZIfKyD3weo9KYj6k+Bsgl+FWgspyAki89sSuMfhjH4V3CMH+dQRglfmUg8HHft/PrXmn7Odx5vw0ih2lTbXt1Gc98ys4/RxXp1IYVHcwpcQPDKMo4wRTpd5jcRFRJg7S3QHtmnAggEHIPegDy3xL4fe2kdFBbupxww9a4W+tHjD7U3MOSBX0Le2kN7CYrhAy9j3B9Qa4DxN4R/jSPegwFcHAGf73oPfpTTEeB6il3a6k1zbs0WRgt2Psan0a1ne6dyvluRl8jh/cV2V54dNtM8Uj4iK5QE5APpmq8VisEWEDgA7eDnHtmmBUjiXJXGD6HpWZIBubleGwQOAfbFbFwPIilbaXXb821QG4/wriNNvZWlZUlfAY5D89+9AFnW5I2t1WKMhw/KD5Wx7g1QgIPysCWHYjpU9/dG5nXzjlRwp/8Ar1FAHaRo1cEducmkBdhVpJMQkq+M8tgH61dSzkcjdG7YG7BOPritfR9NjaFWm8kyNwA3p7VqPbxrhDFFnbwVbBx7UwMyDSxwQpyccZBIFa1ppsKeZIFLMSCVxgfjVqxs4Q2VYMR0Eh+4fWtBEMmFG13B4Uc5+ntQBVMRVAF2DPRWI5rOujDdK9uzoHBwWGMj2BrRvpFjjc3EixY7FOa4q9lEl4kkdy4JbKsqgY/DuKALVjff2RetbvCyLnKuzHNdBdXiyW25YjtxkFW/zmuM8SMHlSUMzCMDcYxjH1BqxHqWxI0fftKcMvAxQBU1+dJNjxFgxHCuQMGuZiuVFwNjFiw5B7Ve1aRXcsGV93Xtiuc+1Sm6RXhWMMcBt4INIDoZYW8tleIPGRghlzkH2rIPh6zMnmCxhjbOQCMD8q1bSRwoBD4J4x0q48DsF2NEvqOv86AKkEEkUeI0TYOB0xj0xViOGJgGaQs2M4UAVLARA4LSRNyWVNvp2pGcRjKxhz3z/DQA6NFUMyIyg9T/ACzUVxObZodlxtIJLLtB3DHQnsO/HNVJbqZywXIUHJIGBWFe3BuFMKRT/M2C/bFAEVzdPe6pA7b3jD7Yxjj3Y12s6pDZhpIyAE+Yn+lZeh6Ovli7YhjnIVj90D+VbtzayXUJZzIsQH8LDJP0oAo6NpSyzLfS26hyv7rfn5V9a6A6VFekm6MUUSEbcHn6mmRxRxxKfPkIA2/M/QY44/oKFEUVuhck7jjB+ZmP07UwM+606BICI1OMnbtOfxpmlW0aDIiV3QZG/wBT0rSlMcjbCXEkhCA78D6ACrtnZLAhWIFSDxhc5oAZFblT8vCYwUToW7mrMSp5kaqSSTnn5ix7fQVYNjHIYyzSN/CcjGR/+utvQNJe8uwsESnLbAFGN/8Ah9aAOj+Huji8uSZEbyYTmTI4Y9l/E5J9h716rWfoWmx6VpyW8eC2S8jD+Jj1P9PoBVHxDrItZ47OFyJWG6Qr1Vf8aQzeqtqd5Fp2n3N5cECKCMyNzjoOlOsJFls4XRtwKjn1rzj46az9k0W10xCd12xdwM/dX19iT+lIDwvWr977Vbu6m2k3EhlbA9T0FUICshQnkryQv6CoruQrPhiOeB3P5VNCDIwUyBVzkhRzimIR9pXzAhZgO/OD/jUmw/NuwBjhR1JPrUpxwDk5bgAYGaVVO8j5S33stzg0AZWuPHbWD3MoaQJjKJ1xkLnngdeaoCz8iXTIJJrSfz9IeZTbTLNGAb24OCw4yM10W7bIpDIQOrHvz1/nWBaqfMtXX7wspceh/wBPuv8ACgDE1vTUvrNlZQbgk7Gxjt0pum6Dr2twmTRdBsjb2u21fZDv+dUXcSx6schj7tWpM7s26PazZGN3T6/r0q74W8eeKfC1rd2PhnXGitHunnkSPS1uQsrY3Dfg+g4zxQM3rqHeAVeNlAACvxXP6nuR0bZuy4Vip4WunZWmZGJJQjHzAfpVLWrdpbZhHH9wbiU46e1Aj2T9mS/Emj+JNOYMHttRWYZ6bZIUAx+Mb17RXzT+z/rK2XjxYGMsUWs2bQmNl48+E70+nyGb8hX0tSGJjk8/hVawDhGDggKzDkfeOeW9snPFWqD7UAFBGRg8iiigDntd8Ow3cbPaxIsnUx9FY/0NeY6zYCB2jMUYGcFWBB68/Q5r2+vPPiri0W3uVMaeYCDlc7iCP6GmhHjXim4W109hHOcqeVz2rgdDQCGaQBiZSXGG7Hp/+qtrxprEUtpsZAfMfZuUdc1Shgiit4IonBVVGA2QT+NADl2MoUN8+e4xXTeE7HN2jy4YAfKcDk+lc6kSthmKfe6knGa6TR1igkWZw4QDaSOdp9fpTA7YQRo2TFslHXGfyqdlmSNTb4OBkgAce9Za3aBUdL2Rm2nAYYwfSn/bIjADJdbZDngN0oAstduhbzBGdp6j5Sfciq13rNpDCyPIN7DKqo4/OuZ1ma8uJYo7aQNgYJB+79D3rMWxCjN1KWHp5mT+lAEl7rN3dF1jeRcMcFvmB/8ArVVtzNGVkuYI8vx5m7AA+lWwlphWEU+7pnzMZ/Cmyx2yyP5wURkZG5iGz2HvQBCzGaXBcuM8MvI/Gql3B5kbIDumi+YYPb6UzSL+S6RvtVsLMq7Lhjyyg8HirzxwNE7hmDH0Xbx6ZoA5yVn2ngZPouazptO80hlZlY4PynBFbt3arHKJLaVnjYA4IyR61LGjn5XLMvXAWkBh2s9zazFLq4iRGYBAEJOe1bVvKEXkfOe2M5NOktN0Y2vEA3BD/eH41GqtE4h8xERT1IyRQBPHKFf/AFLKCcAjofzqK4ZhJnlDgkg+tV5pnLH98XUng4xVOa8bKwssrsRgMwyo/HtQAl9LG8gQyOHOckHqPes3TFEupSI+5W52qMgYBqxcyQGIx30yh88D1HbpUlhFGXaSMlMfdIwSfr7UDOvsE2WwiTbgAZwM7qle4VUKzLneQig8flVKzvNtuHcO2O+Mc1g6hqkcl+kbSzkj51OOv+FMR3kMPlxowhZdvJLN29qJ7dXRYwoQseeCcfjSaJcwXMEON0kwHPmHpW1axkzxqzxqXbCpt+9/hQBnCwWSeFwyAq2ehyR7V0NvYh2Cqyq5bk+3eug0Lw1c3kyusOSO/ZR9e1dxp3hSKHm4KD0VBnj6nvRcDhtL0GW5nCRnzBxtRR+p9K9G8O6FHpcYd8NcbdowOEHoP8a1LW0t7RStvEkYPXaOT9TU9K4yO4cxW8kirvZFLBfXA6V5XK11qPiGe5YO8aIA8ecFmJ4H07V6nclBFiQMVZgML1JzVXT9Lt7G5nni3F5eu45wPQUAXIY1ihSNAAqKFAHoK+dfjtqhufGr2a5xaQoo+b7xI3YHp1r6Nr5H8d6kdW8X67dQsJImunSJ1Ocovyg/jikBzMxW5laNlO84IHbj0rSsYgqCZyASuAM1BawBpTneUAGFxgUmsTx6fplxI7EELtRVXOCfT86YieFDdXBkLbIh8qLnt3JqYgEt5bZJ4JzVHTYdtksUmXfaC5JwM1b8xF27IWIJ5dhj9PrQBV1MTNbSx6c8cVyCvlsWyc5GeoIHGfWoI5LWY6e2nWc8IOlgSLNKJD5gvLre2RxgtnH1qy0xiYu6pEqtkseAOepNZGnF/s9g6hnVtPZ8jpg312QffOc0AZmqSMIrxFIDGGTbtJyW2kAD8cUfECe6jm0BPBk11/Zw0WzEp01n2NP5Y8wts48zPDZ5yMGqcs1zLKkil0BlPOBjYKI0lt932W/urRXYuyW0jxqW6EkA4ycfypDPQNPvElAguVkU7evHUVpXSNI6sAecENjhh71h3axXEh8pQswPPOM9q0tIvpIwbe583jjBIOaoRpQ2TQwi7snkt761mjubaQqGCyoQQCO4PQ+oJFfT3h/VrfXNFs9TtM+TcxhwD1U91PuDkH6V85RELEu5ZAoH3ygJA9/b3r0j4RXZsbm4s3vI2sroCSGI9Y5v4sHvuBBx6qfWkwPVaKKKQwoppGGDZb0wORTqACvNPjw5i8MWsisRmfy8YznP/wCqvS688+OglPguMQhCftaE7jjja5OPegD5Uub6N7+YSPyJAsQb9TW0z7s5WQqMA4YFa5KW5aLUhMFYKHLF8Bu+MflXUwyB1B83cjDKtkD/APXTAlRMKrRsR3AJH5Vs2zuuGKKGK46k4H4Vhw26Fg2c55Plnp71pWsixKMPPIvcvwKYjVWaS3jUySjyMcHHXP8AeqtazXN3OUBhhtVOQcZ3f/Wqm8qzSGNYyofhwzcN+NakFt9njEMdvGUA5LHJ9uaAJxIsUbAxRtsGcxng/hWVLqEcLqkBj3s2WVU3bR7mn3M6x7I1Rnzz8oOQfpWa7TR7Q4KKGJ/1fPPegC9cXrsdyCVT7gDNVJLxJnQyiRh6SAnmmxhnfCiYsT0xj+dX0sL2WMM0luwP8IYbh9RQBAz2LFgqGN25EjjGOKbptzE6Ml1GzJyDLnGfYCpjp5fcFgO4dQW3Y/PpSfYnyyskeVOcSuAVPtQBZtWgUbLeKUQquGbIJP4GhwrqqCHzN3I52sB9aqrDKqEOVlweo4/Cp2XaADF5Q7NuLD8xQBWuLUEsvkmLJB3Mu79aqSRpKW+ePKn7zKa1jECm1UZefmZX3D64qhcKwP7uQlWBOADkEeg+lIDLmy5wrI/vt2j8qo3SvI4dpGUhegb5fxFaFzIxO0NubOcbNpFZd3aSGGRnuTuzkbeDj0oGQfZ4ZZAbq3ULtznecHHetOwjhmYMqqsAHG3jd9BVbTbKZYPNuHZV7RuB8o+taaeYyxhNm3hh24oAc5KhdhlTHGO49q5yUXA1OcZKkrkGQ9fpXUW5eMc7mxyq9cfjWZd3drFO7XKg/ITtPJOaAL/h7UJxEi79uB82w9T7e1e+fCPw+uoaWNWvAwgk+SJC2TIFPJPtnP8Anr8xaddW9jDc3Dv8iREqoBPQE8e1faPw0s47D4e+HIIkkRRYQuVk4YMyBmz75JouB0cUaRIEjUIg6ADAFOoopAFFFFABRRTJpUhieWZ1SNAWZmOAAOpNAHMfE/Xv+Ed8E6ldxsRdyIbe2CttYyuMLg+o5b/gNfL9vpTWlnFE+WO0cu2SPc+9eofEHxHH4h1NJ4RutLTK26yDA3dDJg9+w9BXASossm93DAkknoMU7CKUVsE+6ock8nk9qz79kub2K1t4tyx/MxP3Rz3Pr/hUGp6w4kfT9GQzXWPnZXwsee5/wq5plibW3VXSaaYj7x+bnuTQBaT91KNqszbdpPX8aR5DuBdt57AGpRDJyJF8sHgjuBUdxtLIqsFXblsLz9KAKN8gvYTbzKxjYh8KRkkHIP4ECqd5JdO1xLLe3E85iWAPMVwEXJVQFAAALHt3NXxKqyP5YjXP3cnoPesPWJyLF1Xym8wlRkkZ46UAYO+Ro/MWYlCm0MzDJ49Pfr+FRtdtEFEsi7iN2N44okjXzTBFaRB0QAADO3I4JPTPXmqF5uSVUAYlVAPHf04pDPYVjQTrstwxZSNp7+1QvAXbK2xSYfKFJODVi6f7JGVSFymRuVzkr7gipYbt5goXaQTyq9eKoRJol9IqCCW3kBHTd2HTB9RXTaDqIsrkxxusaqQxUoRjngg1zeIJn8xXeNgMEZx+PvWjbNHceXIs8u9V6qRkkdjQB754R8S2+sCeze4jfULXYsoXjduXep+pXkgV0ZPI4P8AhXg/h7UWhuIlN05MZGGCBXU9jXtWiX41HT0mIAlBKSKOgYenseD9DSaGX6KKKQBXA/GW4MPhqEBo48zbvMkGVBCsMH65rvq4b4uLIfD8LRMN3mldpQNuBRuOfpQgPjy5WG11S5W8YpErMcqehPOQataDcFv3chfyuiBICe55zUfjdBHeRkpH5j87iPvYxwRV2PUbdzay28hjeQbCi9FIpgaI8voGI4xu2FSPw71P5u7Adnf+6G6HHvVcz7iGkl2n6c05ZY3UIyZJ4xn17igRt6LHcYaVEjDuOAxGNv0NaYS6iV2eUQsQcFQAp9uaz4kiW2jUNvVRwucH3xUd5HB5Q8loiP4kkOWH4UwKczzMxL3IU9CV7ULNMi7lO48ZKknj8aWN0BAjZGAODlTj8qspbzSkASJyM/LEcCkA/S52kkYeZIV2nAYdD/hVmOCa5QOVeUA5wQpC/T0qKKOSB8NKFyOQQf5VJJlixd0BxwWGN3timBLJbrIfnnBcDo45H5VC1ttUb2ideuWYDP581zyajKlw6COPCnIcNkVHH4hjuHcJFE+08sEyB+dFwOoSAAMkUD5xkbSCPzpnlKrAfZ5kxztOdpPrWJ/bMHyrNBdBsZDIDsp39orIPlIZT3lYjH4UAbEuEXMp2svOQuR9Kyb29YlWVnSRRwBjjPtUb3Q5Z1bnqQ5wapPK8zNtRApP8RyfwpAJPLNPMqGYHuxJGRUMNhFuEjESdSMuT/k1NHBbwuSYDJLjG/dz+HtUm9eN8adM89SKBiyKFjH7pSe/zZxTWeBSd7RjA4XcQT9KUNHgYCqegGP1pNyKT/q398dfpQIcLhFQkAMAMBd3Ga5+8c+bIJkCSSYDA/wKewPvWhqcElzD5cDqsfJZtnX2zWYkpudQtvNcrvxjMZAIHpmgZe0TRRrV7BpZnkCXDpBI8cZJAZgCAPoa+7IkWONEQYVQFA9hXzL8HtFml8SabKHkVftIc/KPmCfPyfTjFfTlABRRRSAKKKR2VFZnYKqjJJOABQAMyopZiFUDJJOABXknxM8W/bEOn6dMVgP3tq5MvufRf51p+M/GPnW89tYBvs/KvIBy319B7dT7V5FfXXnlpJPNG7JLMeX9qaQhs2/AeRzIoGBlgFH4Vx3ibVrm5BsdMSIbgVacHhfYe/8AhV3Vrma6byLeJLeMjLEklsU/TbGCziV2gMkpGRgdBn+ZpgY+iWbaba7YQh85htIU56dSe+etbyS4DATMSOMKDgn0qaQRrhvIMA64HO0egFVyymeFgxCHJCggbfwoAecKoYrKzDgZOBk+tQEtsKhGOM4LnqaeWVGCYkY55JHU1WubhlKssZWNQctu/p64zQBDLCANoCPO5xnoAK5LxTdrFdxFBHsiJBfBO2uikucrPM2FRVwCTiuN14q4QruIRiQS3Hvx6f8A1qQwtlaGJ3meNNzBlQsST9fXms65uljkw0ksZIzgYbPvWmViigimNqjpwOGOWPHP4c5rl9ZnLXzBBsCjbt64pAe9RSo/AtpchdpDZ5otliDOrMUlODsZecj0NQLdBiEQv5g4ww49qdd6hLbFZLiAuB8pIO1hnvVCL/kEOGSWRVByVMOceuDQqKv/AB7TbeeQ8eMe4qrZ3nm2wMTgEthgz4b6+4q9E/mhvN2MWwVZ2I5HUcUAWre4uXcKJI0bHQLnOO9en/DvxEltdvHdyEJKVVycBRn7rZ9skH657V5TBtRiBJsAYNuT5ihPXB9K2tIuLu3lIe4jliJAImx8wPrQB9J0VzPg7WvtVtHZXjAXSL8jFs+ao9/Ud/z55x01SMK87+Os1vD4Lia5VyDexKhRtpVyGwa9Erxn9pK7V9L0XThc+XuuTcSRggFgqkD8Mk/pQB4F4ziguxbyMZt6kghgB27VxmnsZLyGJQQBKG+bgMfr3rodWVb7UYFmn/dodiMW7HsfrXSx6S62yQvapJbqA0bcHH/16YGXEtzGccMO6nAyPY+tWoQzOoaPgkAg+vsaqqpa6mjWFlQEBGLZ59KtQfaomAOQM5wFoA37dp1kUJCjKTkBnAOahuW8+6UTRQoM5xj5vzpVB2/cxnnNNuxG8gKSRo2Mk9WpiLYulj2JEJAegdcZx7ipQspjDSmZkIPIO7AqBJJpAHgulkYjDKUAyPrVaazyyvskVzx+7Y8fSgCy9xDAVK3WUA/5aj5lP8zWfd6uZY2SGXzXbg5hwuPY0g06MkHdI8gPQ5XFXBZFU3rHEQOrg5AoAxl05bhQJ2iZcYMeMA/U0yS0SEmNI4tijG2OQce1aeopObQfZ9sTD7zMQQV9h6023mgltVSOOKdV4O4AZP1HekBn7JXQkIOnAYniqCTXElzNHG0MkkQ+aOM5IzyM+la9zdXUeowxR2iPaFT5reaCV9gKitrfTYLmWWOzuFeZv3h3YLH3xQMzLmKYvETHOh+84LDb9DVq3mXAVgDyR93BrfWKEoRHp0iD++rEg/WoZYLbcQwunkHOQNqj0AoEZWY844XHcDJ/PtQUAIYIcHuACAKfNYzxl2jDKvUhSGHPrUMSnaCWLEdSTtyPXFAxys7fcaVQOhdRis/Uby62iG2+RpTtE524HtV2eQLE+ZGzg8A5z9K9Y+B2m6F4z8JT6Jrmno1zp7ma2l/5aRo5JIVvZsnByPm6UAeJxavNJMlpNEUiQYxtxub1z6e9aGlXH2rVYbaCRQwOfmXrj09hXf8Axd+D+qWFm15o1o2rQo2d0AxNGvfKj7w/3c/QV5D4Tmt7bV43mWUPynLfmCKAPq74M2kkr3F3MEKwp5aFPukt1IH/AAH9a9UrivhDCU8GwXB2lblzLHhdpCYCgH/vk12tJgFFFFABXAfEDxKscEllZylQrbZXAByw/hHsO/0x61reOfEH9lWZt7aTbdyLncQcIv1HcngY56mvEtbvVKFrhNkmeg/h9h6/WmkIgvZxcYhZo5kUlnlDkEk9SR+dYF5dLLcutujPgYVd3QdMk/rS+dPdbUtYzGmfvkDGPXH0qSONowcB9xYElUyTTASysUthvKu9zjc7s2AKlkLvGgJG3n5t+MgUwzIxCGaaVuRhuF571zXjLUDa6XKtqCkjHy1CnJJ9v89qAN1LmCR28pftGD0MnHHeq8hjknEjp5e3gLH0I9a4rS9Tksre2so7YmduXYMBjJ6H371v2G9EMtwI8kEDDfdpAakyQ53l2+Xpl8/jj1rnNXvCsqwWyOzNn5z0Hqa0pCZkMjbBCmfl6E1i3apNISIVZyNo456+tAD3MUOngkMyg7s43ZC+nvWBqt4bmJ4hbuJM/wB3lfQfWtm9lRWWCNnDRKBhe30/Wsi+aSC1zFMeOvIyT3J/GgZkW8723mKWClR0I3YI9v8APWudlYs5Zup5P481qakfJjYKeXOMg54HPWspx83Ax7UgPor7JJINsx2gkLgOBg/WhYbuAoskPnxjKgkhmxUFtJE42BXd8jg4wavAswxHBMr5+ViNufb61QhUkt5ZDHLHEP8AZaLawGKsWsSwyDy3bew3Abcqfp71DJ9plQMVYtGNwZsZHqCaSO6jjULN5hRTkKoyQfrQBuW9tbFiyzyAngjaAQfQCrgtEVy7JFMoH3jHgms+xu7a4A+ziUTL/Gy4J9jnv71dF66JiSJ4phwz+YuCPpQBqwaq2kRmWUTSQoN+FbDpjkEEeldn4Y+K2g30aw6leC3uAB88iEB/rjof0+nSvOnY3MeGKSRnps7/AF9sV594q0v+yZEuhExtS+3cGGR7UMD6Y1j4leHbG0eS3vorqUKSqpnt618wfEHxPceItb+2XX70jKRFeSiE9Pr06cdqZDEL+FZrWIMmTvI4K46ZH1qtPoNw7GR5GZW4JD4/LHcZpDM6DTIU/f3bNK2Rjbnav1FXb7xA1nbmExSBmQ7Du+Vz6Z7GohaX1tP++nhaI5AdIyH9t3ODVPWrZrqzYm8LFOfLZAMEf/WoAm8P3C3Ly7InDMQxC8flmtjyn3kKXDKc4ZsE/hXH+GJGWdwyI6sArbiQQR3rrkeJgMkgjg7h/nigDY064bK+ZCJgeBzgn2NaUk0LbQ1rcbQMAHBIrnLaRY2bMT7e5Bzg1qw3DxkbYAWxlcnBP0piLJluIGBtkiaEjOzuP/r0JcocmbMa9zH95fw71DIyzMGkPlyYwVUj+Q71GbfC7vtRQk5DONxH0oAslrWTDtfTyr2kZcEfUdxTLuWXyylvM/zLhXMYA/CmphQDLPbyufuqpwWH407cCmx4FXJxmIhjQB5xpGkeI/7aQ6ml08B3LO5lBVlOeVweD0+ldN4c0a20FLiK2aScSvkrMCwT8v51siK3JISN+vVeCPrVkwAfJHdTxseihMjH170gK8ccJYMZI1+b/lnyKkBhaRTvnODkGNQ4NW4LWPCrM6rn+Mp/WlMFsv7trqVzz/qACFHqaYFZrO45dZQ6eqnYR/wE0ttNdQyGPYpJ6rJgnHvTbiwsdgk8uaXn7zvsY/8A1qp3Vs4xHFGi44AL7Mf40AaN5DGNpkQSKTnytpAH5VzupQR21wJnYxW8nQyR4Va2bCaWJWAlPA+Zt2RVDWdtzp8uydsg53Mdwz7CgDK1BYlgcMrFZBjcy7c103weu4/Cni6wvxLOtrM32ecOx2LG3GSO2Dg59q4axabUbiISnzFjbjaeCR3rsJSEs2JDRDGA2cqTSGfXF3fxRyvawS28mpGFporVpQrOBxnHULkgZxxmvinxsNQufF2o3upQGHUbiYtMm0L5b5xtx7etOGtyWXiSLXrW4J1m3bd9q8zJzjB3k9RjjBr1nXNN0/4w+GP+Eg0aIQeJrJAt7Zof9co6Y9SQPlPp8p7YQHp3wUvzffDrSt4CyQoY2X6HrXc1438DtRey0wWE0MhYPtwFxsHYY9favZDwMmgAqhrOpwaXaGaY5Y8Ig6sf8Pes/XvE1npYkQSI0yrklj8iZ6ZP9BXlXiPXNS1eTyrV0aRxtaVmK7R6CnYDM8W+IBd3xNub24mD/O46MTwT7cYA9K5SSyd5wxUtg5w0pbb9a3Le1azVjJcSHJ4Z1496qz367JMSp5a4A2r1JpiKTGVV4iibnkgcEduaSPzwFQpJDuHzBTuz+NWJJ4HLqshGAScHIA+lUL27SO1U+e/K5B3bSPf3oAbe3q2kBkubq32kD5XAU+1cTq1xd6lfNJBPHDaIuUCrksfXntVme3fVbhW+zXEiq5fz3HCnpkfnWrbWVtECXlDnpt4OaQGHo2mKrySGMq8jDLynczY71rXcYxGyGMhScntVu6VxhkeNCmMqy9R6Vh6pO1w4iLKJGbJVRjA9BQAX5ilYIDJjoQO9VseSJGAAz0UDv2yfypzvIC6gEEcBiOM1j6hKjFkluFYjqgk2nr/9b+dAxS07N8zsSoJ2wnAbkjqeeOKpajEptv3UK7V+XcRuKk9/zq9b7okxbReXnp/Go/Ee/NZWsX3+iyL99lGA2NvzY6+9IDm71t87beikDPv3zVVgQetevfGjSNO0/wAOfDWTTrG2tZbvw9DNcNDCFMzlUJZ8feYlicnnmvIXHzHIIzzQB69Bq9nHJ5F3C6SooIJbhx2Kn19q6jSb61uogLZzJEOV3NyvqM15g12bq0FpeRypIcFJQOCR/EM8fhXZ6HZ23kxtbusUnRyg4J9aYHYxNICuWG1skHrkf/r7VNHI4ZlREjYnhCADVGC4kVNkzMcZB28Z96PlkcMoLliOSSTnpTEWbmOK5bEqzW8xwC6MCMj2qK6sIpV3SzSSuRhWU4pMgGRGaSPnIDdCaWKIDGyNEJ5w0hAYZ5x70AVLa5utMO2RFVC3O/kH/DNXp9Ssbq3ZXaOSGTiSFiP59j6VMsMJdwSW3Doy5A/GsrU9IYoJ7OLEhPzhSCrD0I9aAOburM6FqU0VjFK9vcNvUK+ShPqPT1rXseITJJOBEGxIHH3fw9KoWuoQSao0M00UdzGmPKYckeoqHxHei2tVliISUMoyADkZxgj0pAdda2y3MTRSJEyDlWbv9D61zfifw+biAvDGCwPO1MkYrf0e3mkso7lAk0Y++rH7vuPerczsrF3MnIBZkG0Y7HFMDyTRtNuI9RUNGsI5BYnjPbH/ANeun+0+TNsuCg2/LlwAD9DWtq2lwvuurV1Y5/eA8fjVIWNkLMfaU3Kw+TcuR7ikBEW2ncjLz3C8fgalhupekZyOpDLjH+Nc7NHNYXuILh1tpGJ+Y5Rfb/PrWhLGZ1UJJhz0ZTj/APXQM3o7v5dx8jjjAXDA+5qzBcMX/duzLjB8tF/XPSuORdRtpGN29u8QHLpwx9yK0Y7iYW0c1tNFKrDjHAPvQI6MNEFIMwRS2fli5X/Gj915jm4KLk/LI0RXcPcDvWEmqPbyqLiXaxHDEd/SrKalNglTsY8BgOT9aYG48iwrsRxsyPnY9fapFuoYoxuRfKYc4JYn8O1YyzTySKp3bm6uy9T6Yrbht3jT907RyYzvfBP4CgBJLqwdN0cAbA4352n8KgUWsiN9naKNvRRjFT/YfNcvO6ufXGCPpSvZRWzFrSFnI5L9SPY0AZ2dsv7tZUXGC8gzn6mmT27bCY4oXBGciXP481p+WLeMzSgKG+42CT9CDWXLE125kaHzAD96Qfu1+nvQBZ0hNu9goUr9593P5VR1lhHYO3lxtv6EgqzVpZCRCPZG6D7yPyfw9q57Xbhp2whIUY4cFv07UAQaK8UCnzbMLKRhFD4C+9M1HUZZAbeGMISMln5A9MVb0yGPyx9qiwD3UErk+3WtG00S3gKygRx3Lncdsfygdsg8k0gMDSdGlaMPMYFQnITbje394nvXc+Dru88NavDeWDKZUIEgUfK6nqh9c1HHbbrhUc5mYELu5AHr7fSut8O+E7d7EzNO0ky5DAvg5Pp7mmB1+ryWupaLN4o8MhhNGCbu3gALo/VjgdSOp9RzXl1x8SPElxbtFFetEvQMo+Yfh61v/wBsX3gHWP7QW2VbR8Ry2okBMy+mOxHUH+lJ478IWM8KeLvDVw7aNc/vHiVARbt3OOwz1B6H2xhAYGkreTFZbtpJ2chm3jcxPqxPFbNzfQWtuQ8REjjCgYDHP+Ncfda9FaLK6TrI4AVGYkKPw9ataDObqR7q6uUuZicJleQfb2pgaN29zK+2OB844z1X3NYd7aXENx5ZZWIXfgHFdJvklJEbM0Y+8AcbqqXsHmsZJLdo5x8q7WG0r9aAOahs55WeONWiVjzLjJbNWTptolzl2e6mC4BZuAfYdq0jfG1jAuWkfIx8i9PrVYSi4O+OJooz0AGWb60AJMyIRHl0GMBVcBfyFUJSjOdsBVVHG1QSxrQkdVHmO1uEQDcGUKCfTPeud1LUkt1Ij5lbJwgwBz0+lADb+dLdGIaZZRxtHU/WslrpImC7JQ5HLbSfwzVW5vo1leVklaRsDzT9wH0FI1xctdJHCisqj5yp4B7Ae/NIZYXbJPCrMdzsdpPYdzWPc3MFxeSwpsm2EqpaE5BHbcO3X8jWq5GCxBjCknLj/D/PFVP3VmjbZFQud5CjBcn/AOvQBHKkCQ4kdoRgGZkbcQT2rkdWuWubqTLs6puALHr1/wDrVteIdSEY8uMjzMfMRjrjOM/56Vym7BOeeTn3pAez/HYg+HfhepYZHhe2OM+qpXi8n3zz+teip8W9YOlaZp+oaN4Y1WLTbWO0tm1HSkneONVAADH2ArF1vxo+q3STPoHhm0KJ5eyz0xIkbBJyQO/OM+gFADUnme0PlSvIkbhgSclR9PT+vWrula7Lb3ClpwoXqCMfnXNo8kf3CQc44PXNTGXzCjkENn5iP8+1AHsWk6pBqEKlbtQccKozk+ma2DKroNxfAOQehB714fY3lxaTB7eRcD5sZwD68V2mi+K4pBsuklRs4yx46Doe1O4j0JZYlkO2XaSD1UNxU0d4ys0bDcCMxuFBxxWLBfxzRkxGM8ZKMo5+hqV76dViTYJIt21h5m3avqOOT7cUwNCTUFD5ui0a4xscYwfXNMju7nbm1jWTYMFdowR/n+VQvCZdrKy3CjgFx0HuKEa2OQ5ddp2ls7Qp96AM/W7KLUVFz5aR3kXBdU2yLn9K8116yv7e8e4uZGlAOBLyGXnpjoBXrDKjEeVKDLgjdyQe4NUL+0jukLXEZyV2SJ6fh6UmBP8AD/WRc29uAzJcx5UqORKvfnsa6vV4BG8csURaCRcKUO5CD/KvKrOK+8PapHJYOxjQghSOFxXrmm51/TJJIGki3IXYREBQepOPrTQGBuMbv5dvLMhPzB+AB6H/ABrD1yymkjE0Ecixj+IL8oPvW0l9L5m0XqzRglGDDOD6ZH9asyxwNzKgbPUEkZ+mOv0oA4pAl1ZkSQpvUfMcbgce1ZUkVu8xhuH3huY8nAPt6iu3lsRFMZYRb+UVwGEZFcrrmlx3cpEh2TZGXHykD0pAVLQyw3BVIjNGpwp35I+uetX4x5soSGOTfgnOAEH1qpZ2MUUq7D5h6MytkkD1NbSQyFV8ott/unjdQMghhXJWaRVf/wAdb8TVyG0yD5QwT3c8H2pYItpCzpAxP3TKavISF+9Gy9PLU5OfamIfpOy1mcGLLbc5IJA/x+laNuPOQ7XRxktgDOPcjtVS2nGcFnUnryd34irCEruMhiffx9wkj8RQA5nt/O2zEDd0YtwB+HSnST20PzzyAw/w7X4P4iqIgXkswUk/dAOPxqRPskJHkuqy46EZU/QdqAIZbj7dKJIlBVR8vmOd2P5YphiYtvuZVQfwskn3fwqeeKO5XfLcKHP8I+XP0qjeTeRGfMSEMeA6HJH17UAJdlVXCTRu/UDkAfWubZjJe7HDAL8zSA5GfT3qzdzG6Ait4j8xw0qHBP51teG9CjiRJBbFIY+fnJOW/qaQEmjWTyYnWNthPZth/I1oXBtY5m3efGQPmk68+lWblJHcxSFFbtFI33R+FZhEDSbo2kCA4LHIQt6D2pgb/hGz+03zXPkjIX5D95yT3Nd1aDExhlMjpwCqqCc+3vXO+CxEI5ALhMZyXi4P0OaseM/F9t4Z0aX7GyjUbgeXCigOwX1J7fzoA4L41anaWGs2lsJ5ZjEh3Bv4WP6nil+E3xGbRLl7W+t/P0G7Oy6h27wM8FwMc8dR3HHpXDxWF/rd7LdahiTLbmZGJYZ7E966vSvD9tGqLGBtUeuAM98d6QyfXtI0CXxLfr4fu3GjtJuWSRT17hc8kZ4BPb8zqWVva2qCGzdGIAG3btAB7k9c1TWA23/HuUkOflDLkgfTtUtpcMyZdtpOcbRj8c0xF5wj4ClGUHhFbAB7k03IhQ5fap5OT94VBOF4LclR8oX1Pc1G8KxwgKMOcFieWH40APmkUAkwiRzyeRwPQZrJvJUR3MksqydF2tj+VF5YxPvmQyo3ALueh9B/jXMakHaZbZhlZQSxYdvf86ANC81ezjVLa2uPOnOQc4J9zXG6tqE/kvNC5ig3BRkAF+vTj/PNWpbaDSred47iNXm6KyDkf3R3rBns7y6f7Te5RDwnzAZ46KtIY2K8nmVI5JmCxtv56kj1NXJNVZ2WK1ZoIFJDyhQS3BqrDbsLggHYg6h0IYcfSjUFCwRzzIiZz5cUT5GB6gdee9ICWS8MIijfcscfKRZ+aQ9cv+fSs+7u5JpfMclnHHTAAz2ApnIJkcDcxzy2ce+apXlwcNEABu6kjmgCtczGZ8kjaOABUXHOTS+nQdaRhkH1Hr2FACnBPJ4pCB3I/Gg89On50jHnigDRlUxyFJVYMOMsMEcfy5oXCgMrHGencf8A16ls9R/ci21BPPtsYUnh4/cH8qkutPaICaCRZ7cnIdOcfUdqAIFkV2XjPv8Azq1bTqGJOCnft6f5zVFgWcjAP8iP8/zpYwxK5GCMgMTjp6/5/wAKAN211iW3nRRvaIdELcYPvW/pfie32JHdTuBn7rHP6+3qa4dsLjlj82Tjv/n/AD6U6NgBxnI6FTkn0/z70AexW1zbTxCaKQOjH7ysR+NaC7GbKEgsPvY3V5Jpmv3OnOBGqOC3Qr97p3ru9F8RWepKqxSbJf8Anm4wR7imI6KYXKuWlhSaIcmRG4PvimyQjb5iQ+XjjchyPxqMDJXdPtOCBhsD6Go/LjH/AC0dAeuCSP1pgWpbaKeBWneMbeAueR7jviqlrql/oE5bTrhlGCAWGQQeoqaJrZVzHIZGIOQOn4im3RhkRUuLZjHIPldQQAfp3oAhTUGI3+XFEj/f2AEn3xW5pN1+7QJc7gDjCxk4/OuRgsXs5AiLF9lJ+QtkFT3Fel/D/wALw6re+RPI0cUy48+3JwG7f4UAY8jCWSTIwQTuLZJx+FYWqwTwqpMe6BjlSnJU/wCFeneIvh1q2mEyxNLf26HIeEYdR64/nXE31o9ozLczyzIx+ZHGCPqKAOEuwLN0ntWCRA5k+Qc57nFWf7TWSVVaRgSM4QkEVr3enxbj5fkSo4OQgJDD6VhnSxZSxzWkSll4AJ3KPwNIDThlZl2vIxHUAgZrVtZC6AgymZRgdD+lY2nyS3t6LSCFrq8Y5+zWw3t9cdQPc8V6Bp/gDWp0UzBLNmXmMnJI9yP5UAY8YYNvikAbGDI/J/GpGmKcyN5z4wrJ90/VR0r0HQ/hLfSQB7zWXQHpF5I2j6g1ef4TyLExivyWP+yEb9OKdwPLJZgwVZMSOR96RtoH0AqtJPGkLefHvQdWUAEfTuTXeav8LdehspZLQxTsq58lGAL/AInvXmOr21/pUezVrSWzkc4RbgAEn+6D0NACXlxHFKCY8oegXOR9ayrxUKFY8Hcc5Q8fTFV/td2VYlN8ePlA6/Srel+HZ54zeaiJvKJzHEH27vzpDLWjWBfkyrk/wlsH/wCtXSxYjCQQXjKV5ZM/dHse9UoERXEEUcUBxyAu4r9W711Ph7wvf6nMsNlFLNu+Ytj5EH+0x/lTEZbNFEW85oxIFJDMN3HqTXL6jqnmsqRSGJV+VcDOT3we1eqeJ/AUukafJNdTl0KlpML8vH0rx64Qec0tsgViCFJ7D6dqANG6137HY21rZeYZWPzngFjVSDTmup/tequ+QC2EO8D6jtTbPT3KrNdFVcdwfujvWxHDDLkM87QgcRAcMPekBBb8FJIFRbdPuBUwze+K2oWwUIiDu4zuJ5P0HYe9UJJ8gRxBCxwBtGCg+lRXiXTMVjZjJgDcMcD/ABpgaErqMqwRiCc7T83500MMSsrJhOHB7kc496qQ20gIW4OTnkLn5R706Z7dQCruFX7vynmgCzHPuYyxRbV6naMD8qqzXA3kyhNwO4lmIC0n2iebLDBjx97oazrhIyxeWUbf7g6mgC686SMArbhncQ3Ra5PXdQSJ2eO4Qu7EbmHynH8OOv40uua0lsnlxhchSwUnr9TXGy3BuZ/tOoQiVUHyxjgfjSGTW9teXtwbqeJc+qNnB9vpTLyeK3kYtK895jaMH5IhnPXuc1WutZuLtykBaG1UY8uM8Ht1x3qg0ah2MzgDPUHk/wCfX2pAWJ7q5uNw3uwbl2zy31Ptmq2VBHBeTOBg9/8AGp7eC4vcm2AitlPMjnC8e/fvUct/FZI0WnnzJipV7kjpnqFHb69aAFuIhaDzLph5rcpAD83sW9OMcdfpWU5JZy3U0MS7FnJZicsTyc01iMHvQAE5YdfXjrSHkYGc5pG5IwD6fWg9c4PNAC4B4HB4pHHzd6TJyOelDHJoAnIPAz07f/Wqa0up7V1e2kZCD19/pUAA4yBk84HalQAY4z+uaANqG8sLzaL2A202MebAMKfcr/UUl1pV3bKJtpmtcZE8R3rj1rHBCtk8t2q5p2o3WnyBrWbYG5KHlD9R/WgBI3OfmPOTyOeSOP8AP/1qbuPTGcjgkda14/7L1YAx7dNvSc7WOYWb2/u/T+dUtU0+50+cRXSAAgbXByjfj/T9O9AEKsHYHcTn05xSrI6GN0dlYHjtj8R9etQ9CckHtwep/wA805BjG372Onv3oA6vRvFM0IWO8TzgABvHDD3/APrV21lqcF5AwRo51BG5d3I9K8fwCQCep/D/ADzVm2nlt5xJDK0bj+LPX6+ooA9kiYSYMLBF5yMYH1p8iCSN2inYyj7yyHGcehrg9L8X7HC6kh29mj7fSu10rUoLy3jkikEkTDCs43H/APX9aYh4M8bMyBZIyMbnGdv4iu6+F/iB/D+s27JNI9jcfu7iGRQoQE/fU+1cckqs+4EEjrnA/IVdtC0Vwk29t3UDHysP6UwPrMOhjEgZShG4NnjHrmsLVdN0HXrUTXsUEitwJiNjD8eD+fFcT4F8bwWMEdjqQMNminy5T82w5Hy8fw9f0rvvteiSx/ahPZOj8l1ZTuz6460hnE33wm0uac7dSmhib7q+WhcfRv8A61La/BrwqY1+0tfXmfvF7jarfgoFbWq+KPBpQWGoarbY3cBnY7G/3v4fpms270jVEuF1PwnrCT6aV5ggZWEmPcdfwPfpQI6Xw/ofh7w5GLfRrHTdPA+XEIUOfqepP1zW6iKgwihRnOAMV5fe+LNMGgz6r4i8O3bS2bf6Q1vEDIqjjecEEitfTfGPh3VLTz9K1tYyyAR285K7eOmD+HrQM7Ka/tIN3m3ESlRkjcMj8OtJaaha3jMttMrsACV5BAPsa8B+It1ql000X2tXhXDN5OUJHse/0qt8NdavrO6eAzEQyL/y1OcH6daLCPpGud8VW+h6lCdO12PTri2lGHhuVzk9ju7Vi33jXRPD+hyvr+qAL5Z/dKo3le5AH/1qk0/UNHu/Cdpq+m2D28d0c2/29D5hz/FtJJ+gpDOO1r4MKZRc+F9SRbdsFbW6AZVH+w4Gcex4rLX4Wa/LMBc29sXPAmFxgR/h3H4V6folhrMkzXN0lnp0W0hdgLSMPVh91T9PyqZ/EvhzSro2l1riS3X3mV5TIw57heB+QpiOY8K/Ce1sdsmu3K30oO7y412oD2564/I+/avSbS1gs4FhtYUhiHRUGBXK3PxC0aNykPnzSDkgLtAHqSaw774q2hDLp9qxI6ySEED8B1/OgZT+NWv/AGGW2sreMy3LpuGTlUznnb3NeHtC0zs143LdZFxuPtjtXQ+INQTVNTn1K6jEt3O33t5LEdgF/h+lZQMvLSsDCDwgAH1yaBGfO0YC/ZFR1U4wDwPcmlhuQP8Aj2WdXZcEq2evoO/41pk/ulEcUYUktiVQBj29TVSSaKMKVVImJzxySe1ADUZQNodVYnHzAqc9yTVqOZY2ZYY1baByTu/75qm88zZZ1SQf3sjI9zWdqOo2lkii4nQO44LfKaANp7mZ0YAOSTggnn/61ULy+ERAmcxKq4O/nj2rkdR8TJDMyQu/BzvAzz7eprn7rxFeSK25zg4w5HP15/rRcDtrnXbeKKQ+fkKcHcpGfp61yup+IZbkkQsCjDaCwxge1YU0zytm4JYg/fkOPwFRF4irBQwx3xgfTFIZbIbaZ7iU5z8qg5JPrjsKhnnnuQTcNtjXkcjPWqhlYO20MGzzU0FvJfSuY3jVFUtI7dEA7n/CgBT5jFYbYF2YEADrinS/ZLAD7UwvLvg+SjZjQ/7TD7x6dPTvVW6u1y0NkDHAOpB+Z+O5/pWe3agC5f391evmZztUYEajaqj2AqopJ/x9MU0jvyOBQAQR2J6UAKp+bHYmk/iPrQoyaBxQAHJxnp2o7dKCOKB0oAD1zgcUmfUUtJigCfqQeeo680gbKgZOen+FJuyByvHGMUq4wMkke1ADmxk9uOgzSqfu43Egdqbjg9/woBwR6c0AOX7qjHQ855Faun6zPawm2nVLyyxhoJucD1U9R/SsgHBO0804Y5BIPORxQB0A0y01BA+jTky4ybKY4dev3T0b/PNZDoYGZJI2V0yGVuoPpjtUAf5wwYgryCDgj/69aS6xLMqLqMMd6oHDOdrgf7w/rQBU3IFxyCeo9vanlNoJBB4GAOlWXsoboF9LkLIeTbSEeavfjsw+nPtVKVXRykgZGUYKsuCBn0oAepySpDDPtnt0q3ZX09lOZbeRlYY3DOA3+f8AOKpxnn5jyByOn5U9cEtjBTOBjrQB6Fo/jKCSNWvlCTD5SQpYH3xXVWN2J499lKJoiNw3HePevFVyo2sBk9MfyNXrHULiyZntJTbyMMlc5B/+vTuB7S12yyBpFMTLjlido/CpV1KdVcbz5R4OBgc+1eYad4zu4kAvIo7oDqSdpH17Gtm38V6ZchTKj28n8Dn7p+hH9aLiOwmngeNgkf3vvZHH+Ofen+FtR1Lwfri6p4eZmR2H2uxBOy4X0I7Njow5Hfiuej1GF2DeduBPBOAwPt/hVyK+VdpZyR1yrYJH0oA+svD97Y+JNEF/FatGl2uJoZVw2R1DDofrXlXjT4LyNeNe+EpI7RRn/Q14RiecjPCfhwc9Kw/AfxHOgwLZoytaK+7yZeTg9drdQfrkV7x4b12y8Qact3YPkdHQkbkPoaBnyNqupa9pt6+naxHfW11GDiK7BXgd1PRh9D9cVHpl9q+sXQsNEsLi71AcmKxUs6+7twFHuxFfXfiPw1oviWCGHX9LtNQjhfzIxcRhtjeo9Ks6RpGn6Na/Z9KsoLSHOSsKBcn1PrRcDyH4dfCKQpHqPjmCJrpZBJFYLL5qR4/56Ho7Z59B79a9B+Iviiz8GeHTqctqLm6UiGzt1ADPI3AUH+Eep7AV0Wp39rpljNeX8ywW0K7nkboBXh3xY8ZaL4otLS20yKS6WKTzBcsMIP8Ad7/jikBy954w1zX4n/ti+lWSRtzRW8hjhjHYIO+OmTkms1L1LSN0ttjEj75GCx96qSuiqiGaOSMdGBxj6mq00pwE+WRVBKggA/XNUIuPNdvIY1fIb7yg8j2pcxsQJYtr5wQQQD+XessTxQqPtLLtHJLvgH2yKqzeLLGNCpvrfavQBw+36YpAbyybS/lMsBH3svk/ifWo2nuJPnlihYdA7EDj1rjtR8bWakKkUk+P4lGAT+PUVzOqeJ9QvciKTyIf7sTc/n/hRcD0PVdXsbCLdJMkaYwAxJY/QVzFx4zjdwLWF1/23AwB9M1wrvJK5eVndz1djkntwfSnOZSeBk454/KgZu33ie9uC4imWFf9gDc31J61gySyyMXZ3d26lycn86jIwwPQ9sjINNkBVtu4k47d/akBMoIGXO056k4pC0Skujl2zgM3+f5VCS2Ocqc55Apsh253YJx3H6UASyhy3zNgg4ODjmkiRnKqhLFjhVHJY+lXF0+VkW4vpFtID91pMh3H+yvU1DLqaWqmPSozHxj7RJzKR7f3R9PzoAsypaaYpF4GnvM5+zK3yR+m9h1PsKoX2q3V5EsTuqQL0ijXao/x/GqO485OcnPrmkH9P0oAXpy3QdvWmOcnkc05ieCfypvUmgBXIIwO35Ui9QeePSg5H0pM0AKD8wJ6A0ZzyTzQO1IKAFGPw70AUo6jIOKXIMYG0bgevrQAwijk9jTkxuAbO3vimmgCXrgn7uQCSKDnA4PU4FHVcgZ5Ax+FC8kEAYzyKAHDocj6ECgnnnNAGCQMDH+c0dMe3HH4UALksgCjvz9aTJG7sc9MUnI6jFK3H/16AHEnfkbS2ew60uT8uzkj05phIznOTjnNGV+Xj6+lAD2PHfd1GOv1rSh1W48vyroR3kA6JOM4+h6g/jUukWq3ej6nHDDHJdBodgLLvA3ckZOfTOPx4qI6HqW3cbQk4670/wAaAJNum3JDQyvYvjBjmy6H6OOR+NFzpl9bQ+c0DPCT/rYWEiY/DJH40668PajbLaZg8zz7dbgBSuUBZgFbng/LnBweelP0TS9W/tS2hslltZp3VFfeFA5784x9aAMxCpUYlAAyR81WFeaTbgrlfUc1qy6lqoLw3lhaXoR2RmkgU5wSDgg+o605LW1v7ee5js1sIbURm6LTNI7B3CDyx0ON2SME4oAzEuFCusi/MBnjpmiOcRMxUBx1I69fw6VPcWdpGf3GorNzwskLo2PqRj86Zd6fNZ2lnczvavFdxNLCEkyygNj5h2PtQBoadqSwbEcCQN0wMbAfX2rTFw9oNxlW438hi3yj2DdjXN6eI31OxSUL5bzxK4ZuGUsMg+2Kua21vb67q9vb+WkMd9PHCkbfKqCQ7QCOq+lAHpWi2FxeW6yxSRKTyBJwfzrtfCHxDbwddyW89sJnY7TsIBcDsfUj16155ofiWG30lFtZbK5a3gM920twImRQQMKMfO/PTvisDXNcs5dcaa0u4TGoKh0XJbn3449qYj6VvfjfayQ7IbOWFiPmbqR9PT9ar+HfjBpWmOY7jSr+RJDlp4ZFfAxx8pYfoe9fNV5rUxsbWWRrZo52kWILKGkUoRnenUA54z1qkutrHHlMLMR8zCQ/ouaBn0L8VfiTp/ifT47WyguLe3VtzSXEgXd/wEEj8zXjl54mitZT9nPnkjJKg5Ptmuc1OYQuhmuY/MliWXENwsq4bPVgeGGOVPSqFqi3F0sSS22+X5FMsojAOOpZsAAYpAbs/i27lBECww5GQepxWPca1fSx4e4nYA5LZx+PH/6qzCwQlfMBbkcdz/WtGzSxl0PWJ5nUXkH2Y2oaXafmciQhf4uMfSgCtc3M1xtFxI0uOnmNuA98VAzOBx0A/i4I/OmF4/mBznPBPH40sqPAkDt5TLMm5QJUY/8AAgCdp9jQAxjxwSAe3albeMhjg4zkUyPMknloy7mYKCzBRknuSePr0pD+7kZCw3AlThtw4PYjgj3FAEyyBADkgY45/rTGZsYG7DcZHAJ/KmpmUHDRhUXc251XA6cA9T7DJq3BZCfBa8soVJ/imHH4daAKXU5BwCOD2pUZ2ZY49xJ6RjJJP86vNHpUBcT3FxcnJ2tb7VVsduSWA9yKSTXJo4Wi0qKPT4iORF80jfVzz+VAD30x7eNZ9VmFsOqwn5pW/wCA9vqai/tgWuRptvHEQP8AXSDzJD7kngfTFQa2lvHq10LSdp4A+Emdg7Pxzk9Dz3rOPXHGfagCW4mluJ2luJHkdj99zmo2HI5O49c+tIF5A/Higg+vTsaAHYxkc49/50HIB56c9KTPBI6fzo25IHPA4570ANbO0ZxTfXHSpMqC2QckcUzPFAATzz1pKXFJigBR1GOtHfNIRjqPzpc9P/1UAGOPrRQDRigBKOPSjFGPegCTgEDg9Mk0cAfj1FIcds0qHGPTuD0NAD+STk8Z7fTrSnjtj+tMxyctk+/Q07vjJOeP8+tAAMhVyp+n4/8A6v8AJoK/K2ew7f5/zzQnTjvnjH+f88UE7g2T7+tAARjIz+mKMe3bvQrAHAx+VJxjBOeO1ACkY46gcilI68AcdwOfpS5A4ycZ78j8qRyM4HAx3/lQAoIznaCo9RSgDJwOnU4zjn6UwMcDkYH0pxPzFgcEHjigAVQc8D1+7il+X0HPbbSI5Vy27APB701D2988nvQA8Aew+gxindSO/Hamjg9RtOe/8/WjdkcY6e1ADhjAwO3Oe9KAMYHYc0zIIwCcg9RS5GAe3XrQBJ39eeB3NJ6jk4Hp/n9aYD1Geehx3pQcZGff6UAPBIPy8hh6dv60u7Axzt6nA7VHnkdAw9f8/wCFIGGMggDg59aAJWcfRfz/AB//AFUhwPvD2I/+tTd/PU5HfNN7jnj1oAcDge2emM0g+g/wpu8E4Bzz+H60m4dSe/TGaAHr1zz/AJ/z/wDWpjHGO+eTxjNI3EnHJ68Hp+NITjv0oAcx68kHpjpx+VNX0HrmgYAzn9aOmMnigBOOOaXPbtmheCCDn0xRx/eGcfWgAOeevT17Ugz0OcY7f0pCB83THXihQSvDdB/WgBMFjwSzfzptOOeCT/jQcUALgnr+vFAJwQAD9RSDGOtGR3HagBDnBwMD3FHTGSenb+VL2wSCeg9aCCc/MDn36UANORnPB9KTtQBSkY7g0ADHOMDnvikHYj1oxg44oPQUAHOcn86M0e3vR1oAMjmgdjR+VFACGjBo4ozQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial CT scan through the pelvis shows marked thickening of the wall of the rectum and sigmoid colon with some free fluid in the pelvis (arrow). These features are not specific and may be seen in any form of colitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43377=[""].join("\n");
var outline_f42_23_43377=null;
var title_f42_23_43378="Treatment protocols for esophagogastric cancer";
var content_f42_23_43378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment protocols for esophagogastric cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43378/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43378/contributors\">",
"     Tim Brenner, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43378/contributors\">",
"     Shrina Duggal, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43378/contributors\">",
"     Jim Natale, PharmD, BCOP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43378/contributors\">",
"     Scott M Wirth, PharmD, BCOP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43378/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43378/contributors\">",
"     John W Mucenski, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43378/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/23/43378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15190182\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with esophageal and gastric cancer, both in the",
"    <span class=\"nowrap\">",
"     adjuvant/neoadjuvant",
"    </span>",
"    setting and for advanced disease.",
"    <strong>",
"     This is",
"    </strong>",
"    <strong>",
"     not an exhaustive list",
"    </strong>",
"    ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with esophagogastric cancer. Additional regimens may be added over time, particularly as treatment for esophagogastric cancer evolves.",
"   </p>",
"   <p>",
"    This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with esophagogastric cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link\">",
"       \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link\">",
"       \"Adjuvant and neoadjuvant treatment of gastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=see_link\">",
"       \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15190339\">",
"    <span class=\"h1\">",
"     REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15196435\">",
"    <span class=\"h2\">",
"     Chemotherapy alone",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933416664\">",
"    <span class=\"h3\">",
"     Docetaxel, cisplatin, and fluorouracil (DCF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef73324 \" href=\"mobipreview.htm?29/18/29998\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15190442\">",
"    <span class=\"h3\">",
"     Modified docetaxel, cisplatin, and fluorouracil (modified DCF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79612 \" href=\"mobipreview.htm?35/41/36510\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933416689\">",
"    <span class=\"h3\">",
"     Epirubicin, cisplatin, and fluorouracil (ECF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef62502 \" href=\"mobipreview.htm?35/44/36558\">",
"     table 3",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933416714\">",
"    <span class=\"h3\">",
"     Epirubicin, cisplatin, and capecitabine (ECX)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef53899 \" href=\"mobipreview.htm?36/58/37806\">",
"     table 4",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933416739\">",
"    <span class=\"h3\">",
"     Epirubicin, oxaliplatin, and capecitabine (EOX)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef75288 \" href=\"mobipreview.htm?35/50/36654\">",
"     table 5",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933416764\">",
"    <span class=\"h3\">",
"     FOLFIRI (fluorouracil plus leucovorin and irinotecan)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the published experience in advanced esophagogastric cancer is with slightly different regimens, most clinicians use the same FOLFIRI regimen as is used for advanced colorectal cancer (",
"    <a class=\"graphic graphic_table graphicRef76300 \" href=\"mobipreview.htm?19/2/19502\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=see_link&amp;anchor=H31#H31\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\", section on 'Irinotecan plus fluoropyrimidines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933416821\">",
"    <span class=\"h3\">",
"     Irinotecan plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef62115 \" href=\"mobipreview.htm?21/24/21902\">",
"     table 7",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933416793\">",
"    <span class=\"h3\">",
"     Modified FOLFOX6 and modified FOLFOX7 (fluorouracil plus leucovorin and oxaliplatin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the published experience in advanced esophagogastric cancer is with slightly different regimens, most clinicians use the same modified FOLFOX6 and FOLFOX7 regimens as are used for colorectal cancer (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55829 \" href=\"mobipreview.htm?10/19/10558\">",
"     table 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=see_link&amp;anchor=H27#H27\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\", section on 'Oxaliplatin combinations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H958003\">",
"    <span class=\"h3\">",
"     Trastuzumab-containing regimens for HER2-positive advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef86570 \" href=\"mobipreview.htm?40/53/41822\">",
"     table 10",
"    </a>",
"    ) and (",
"    <a class=\"graphic graphic_table graphicRef86571 \" href=\"mobipreview.htm?39/7/40062\">",
"     table 11",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15196507\">",
"    <span class=\"h2\">",
"     Concurrent chemoradiotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933416871\">",
"    <span class=\"h3\">",
"     Weekly carboplatin plus paclitaxel with concurrent radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef68266 \" href=\"mobipreview.htm?2/49/2846\">",
"     table 12",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20092197\">",
"    <span class=\"h3\">",
"     Trimodality therapy with cisplatin plus fluorouracil and concurrent radiotherapy followed by surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef87313 \" href=\"mobipreview.htm?25/8/25742\">",
"     table 13",
"    </a>",
"    )",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85680 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43378=[""].join("\n");
var outline_f42_23_43378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15190182\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15190339\">",
"      REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15196435\">",
"      Chemotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933416664\">",
"      - Docetaxel, cisplatin, and fluorouracil (DCF)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15190442\">",
"      - Modified docetaxel, cisplatin, and fluorouracil (modified DCF)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933416689\">",
"      - Epirubicin, cisplatin, and fluorouracil (ECF)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933416714\">",
"      - Epirubicin, cisplatin, and capecitabine (ECX)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933416739\">",
"      - Epirubicin, oxaliplatin, and capecitabine (EOX)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933416764\">",
"      - FOLFIRI (fluorouracil plus leucovorin and irinotecan)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933416821\">",
"      - Irinotecan plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933416793\">",
"      - Modified FOLFOX6 and modified FOLFOX7 (fluorouracil plus leucovorin and oxaliplatin)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H958003\">",
"      - Trastuzumab-containing regimens for HER2-positive advanced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15196507\">",
"      Concurrent chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H933416871\">",
"      - Weekly carboplatin plus paclitaxel with concurrent radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20092197\">",
"      - Trimodality therapy with cisplatin plus fluorouracil and concurrent radiotherapy followed by surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/85680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/85680|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/18/29998\" title=\"table 1\">",
"      DCF for advanced gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/41/36510\" title=\"table 2\">",
"      Modified DCF for advanced gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/44/36558\" title=\"table 3\">",
"      ECF for advanced esophagogastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/58/37806\" title=\"table 4\">",
"      ECX for advanced esophagogastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/50/36654\" title=\"table 5\">",
"      EOX for advanced esophagogastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/2/19502\" title=\"table 6\">",
"      FOLFIRI regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/24/21902\" title=\"table 7\">",
"      Irinotecan plus cisplatin for advanced gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 8\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/19/10558\" title=\"table 9\">",
"      Modified FOLFOX7 regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/53/41822\" title=\"table 10\">",
"      Trastuzumab plus cape and cis HER2 adv EG cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/7/40062\" title=\"table 11\">",
"      Trastuzumab plus FU and cis HER2 adv EG cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/49/2846\" title=\"table 12\">",
"      Carboplatin and paclitaxel with RT for EGJ cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/8/25742\" title=\"table 13\">",
"      Cisplatin FU RT for EGJ cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=related_link\">",
"      Adjuvant and neoadjuvant treatment of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_23_43379="Penicillin G (parenteral): Patient drug information";
var content_f42_23_43379=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Penicillin G (parenteral): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"     see \"Penicillin G (parenteral): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/46/14054?source=see_link\">",
"     see \"Penicillin G (parenteral): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pfizerpen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F207661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Crystapen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to penicillin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store closely.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11247 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43379=[""].join("\n");
var outline_f42_23_43379=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207660\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207661\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012955\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012954\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012959\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012960\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012962\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012957\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012958\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012963\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012964\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=related_link\">",
"      Penicillin G (parenteral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/46/14054?source=related_link\">",
"      Penicillin G (parenteral): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_23_43380="ECG Torsades de pointes tutorial";
var content_f42_23_43380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Single lead electrocardiogram (ECG) showing torsades de pointes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 141px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an atypical, rapid, and bizarre form of ventricular tachycardia that is characterized by a continuously changing axis of polymorphic QRS morphologies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43380=[""].join("\n");
var outline_f42_23_43380=null;
var title_f42_23_43381="Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information";
var content_f42_23_43381=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Black widow spider (Latrodectus mactans) antivenom: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?31/12/31941?source=see_link\">",
"    see \"Black widow spider (Latrodectus mactans) antivenom: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/36/21059?source=see_link\">",
"    see \"Black widow spider (Latrodectus mactans) antivenom: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antivenin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/12/31941?source=see_link\">",
"      see \"Black widow spider (Latrodectus mactans) antivenom: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Limited data in infants (Monte 2011; Nordt, 2012). The initial dose of antivenin should be administered as soon as possible for prompt relief of symptoms. Delayed antivenin administration may still be effective in treating patients with prolonged or refractory symptoms resulting from black widow spider bites; a case report describes use of antivenin administration up to 90 hours after bite (O&rsquo;Malley, 1999); however, delayed administration may decrease effectiveness (Edberg, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Sensitivity testing:",
"     </b>",
"     Intradermal skin test or conjunctival test may be performed prior to antivenin administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Skin test: Intradermal: Up to 0.02 mL of a 1:10 dilution of normal horse serum (provided in kit) in NS; evaluate after 10 minutes against a control test (intradermal injection of 0.02 mL NS).",
"     <b>",
"      Note:",
"     </b>",
"     Positive reaction consists of an urticarial wheal surrounded by a zone of erythema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Conjunctival test: Instill 1 drop of 1:100 dilution of normal horse serum into conjunctival sac; a positive reaction is indicated by itching of the eye and/or reddening of conjunctiva, usually occurring within 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Desensitization:",
"     </b>",
"     In separate vials or syringes, prepare 1:10 and 1:100 dilutions of antivenin in NS:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     SubQ: Inject 0.1 mL, followed by 0.2 mL and 0.5 mL of a 1:100  dilution at 15- to 30-minute intervals. During desensitization procedure, proceed with the next dose only if a reaction has",
"     <b>",
"      not",
"     </b>",
"     occurred following the previous dose. Repeat procedure with a 1:10 dilution of antivenin; and then with  undiluted antivenin. If no reaction has occurred following administration of 0.5 mL of undiluted antivenin, continue the dose at 15-minute intervals until the entire dose has been administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If a reaction occurs, apply a tourniquet proximal to the injection site and administer epinephrine (1:1000) SubQ or I.V. proximal to the tourniquet or into another extremity. Wait at least 30 minutes, then administer another antivenin injection at the previous dilution which did not evoke a reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Latrodectus mactans",
"      </i>",
"      (black widow spider) envenomation; other",
"      <i>",
"       Latrodectus",
"      </i>",
"      spp envenomation",
"     </b>",
"     (Clark, 2001): Limited data available for some types of envenomations.",
"     <b>",
"      Note:",
"     </b>",
"     If a positive reaction to a skin or conjunctival test occurs and antivenin therapy is necessary, pretreat the patient with intravenous diphenhydramine and an H",
"     <sub>",
"      2",
"     </sub>",
"     -blocker while having a syringe of epinephrine (1:1000) at the bedside:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children &lt;12 years: I.M.; I.V. (preferred): One vial (2.5 mL); a second dose may be needed in some cases; more than 1-2 vials are rarely required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adolescents: I.M., I.V.: One vial (2.5 mL); a second dose may be needed in some cases; more than 1-2 vials are rarely required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: The initial dose of antivenin should be administered as soon as possible for prompt relief of symptoms. Delayed antivenin administration may still be effective in treating patients with prolonged or refractory symptoms resulting from black widow spider bites; case report of antivenin administration up to 90 hours after bite (O&rsquo;Malley, 1999); however, delayed administration may decrease effectiveness (Edberg, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Sensitivity testing:",
"     </b>",
"     Intradermal skin test or conjunctival test may be performed prior to antivenin administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Skin test: Intradermal: Up to 0.02 mL of a 1:10 dilution of normal horse serum in NS; evaluate after 10 minutes against a control test (intradermal injection of NS).",
"     <b>",
"      Note:",
"     </b>",
"     A positive reaction is an urticarial wheal surrounded by a zone of erythema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Conjunctival test: Ophthalmic: Instill 1 drop of a 1:10 dilution of normal horse serum into the conjunctival sac;",
"     <b>",
"      Note:",
"     </b>",
"     Itching of the eye and/or reddening of conjunctiva indicates a positive reaction, usually occurring within 10 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Desensitization:",
"     </b>",
"     In separate vials or syringes, prepare 1:10 and 1:100 dilutions of antivenin in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     SubQ: Inject 0.1 mL, 0.2 mL, and 0.5 mL of the 1:100 dilution at 15- to 30-minute intervals. During this procedure, proceed with the next dose only if a reaction has",
"     <b>",
"      not",
"     </b>",
"     occurred following the previous dose. Repeat procedure using the 1:10 dilution and then undiluted antivenin. If no reaction has occurred following administration of 0.5 mL of undiluted antivenin, continue the dose at 15-minute intervals until the entire dose has been administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     If a reaction occurs, apply a tourniquet proximal to the injection site and administer epinephrine (1:1000) SubQ or I.V. proximal to the tourniquet or into another extremity. Wait at least 30 minutes; then administer another antivenin injection at the previous dilution which did not evoke a reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment for hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 6000 Antivenin units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Reconstitute vial containing 6000 units of antivenin with 2.5 mL provided diluent; gently shake vial (with the needle still in the rubber stopper) to dissolve powder. Excessive agitation or shaking of the reconstituted vial may cause foaming, which may lead to denaturation of the antivenin. When reconstituted, solution can range from a light straw to a dark tea color.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer into the anterolateral thigh. Apply tourniquet if an adverse reaction occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Dilute reconstituted antivenin with 10-50 mL of NS; infuse over 15-30 minutes (Clark, 2001). If an immediate hypersensitivity reaction occurs, immediately interrupt antivenin infusion and provide appropriate supportive therapy. If administration of antivenin can be resumed after control of the reaction, reinitiate at a slower infusion rate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. After reconstitution, appearance may be opalescent and color may be light (straw) to very dark (iced tea); potency is not affected.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of patients with moderate to severe symptoms (eg, cramping, intractable pain, hypertension) refractory to supportive measures due to",
"     <i>",
"      Latrodectus mactans",
"     </i>",
"     (black widow spider) envenomation (FDA approved in children and adults); has also been used for  treatment of patients with moderate to severe symptoms (eg, cramping, intractable pain, hypertension) refractory to supportive measures due to other",
"     <i>",
"      Latrodectus",
"     </i>",
"     spp (including",
"     <i>",
"      L. bishopi",
"     </i>",
"     ,",
"     <i>",
"      L. geometricus",
"     </i>",
"     ,",
"     <i>",
"      L. hesperus",
"     </i>",
"     , and",
"     <i>",
"      L. variolus",
"     </i>",
"     ) envenomation",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F136053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Rash (rare; associated with hypersensitivity reaction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Muscle cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions, serum sickness",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anaphylaxis and serum sickness have been reported in patients who received",
"     <i>",
"      Latrodectus mactans",
"     </i>",
"     antivenin. Allergic reactions may be less frequent than described in initial studies (Clark, 2001; Offerman, 2011). One retrospective study reviewed 163 cases of black widow spider envenomation; 58 patients received antivenin therapy and only one case of anaphylaxis occurred (Clark, 1992). The risk of reaction appears to be greatest with bolus administration of undiluted antivenin (Clark, 2001). Delayed serum sickness, albeit uncommon, may occur 1-2 weeks following administration, especially when large doses are used (Clark, 2001). Patients with atopic sensitivity to horses may have an increased risk of experiencing an immediate sensitivity reaction to the antivenin; carefully review allergies and history of exposure to products containing horse serum; use with caution in patients with asthma, hay fever, or urticaria. All patients require close monitoring in a setting where resuscitation can be performed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A skin or conjunctival test may be performed prior to use; however, the utility of skin and conjunctival tests to accurately identify patients at risk of early (anaphylactic) or late (serum sickness) hypersensitivity reactions to horse-derived antivenins has been questioned (WHO, 2005). One mL of normal horse serum (1:10 dilution) is included for sensitivity testing. The absence of a skin hypersensitivity reaction does not exclude anaphylaxis or hypersensitivity following antivenin administration. False-negative rate for skin testing is 10% with similar agents. Conversely, hypersensitivity is not an absolute contraindication in a significantly envenomated patient.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A desensitization protocol is available if sensitivity tests are mildly or questionably positive to reduce risk of immediate severe hypersensitivity reaction. According to the manufacturer, desensitization should be performed when antivenin administration would be lifesaving; however, the risk of anaphylaxis should be weighed against the risks associated with delayed antivenin administration (Rojnuckarin, 2009). Some products may contain thimerosal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Use during pregnancy (second and third trimester) has been described in case reports; all patients delivered healthy infants (Handel, 1994; Russell, 1979; Sherman, 2000). In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; hypersensitivity reactions; serum sickness (for 8-12 days following administration); worsening of symptoms due to envenomation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neutralizes the venom of",
"     <i>",
"      Latrodectus mactans",
"     </i>",
"     (black widow spider) but may also be effective following envenomation by other",
"     <i>",
"      Latrodectus",
"     </i>",
"     species (including",
"     <i>",
"      L. bishopi",
"     </i>",
"     ,",
"     <i>",
"      L. geometricus",
"     </i>",
"     ,",
"     <i>",
"      L. hesperus",
"     </i>",
"     , and",
"     <i>",
"      L. variolus",
"     </i>",
"     ) (Clark, 2001)",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1045284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Within 30 minutes with envenomation symptoms subsiding after 1-3 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F16225744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/36/21059?source=see_link\">",
"      see \"Black widow spider (Latrodectus mactans) antivenom: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antivenom administered by injection requires close monitoring. Report immediately any pain or burning at injection site, difficulty breathing, swelling of mouth or throat, acute anxiety, or chest pain. Rare delayed reactions have been reported 1-2 weeks after treatment; notify prescriber if fever, itching, rash, joint pain, or swollen glands are experienced.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The venom of the black widow spider is a neurotoxin that causes release of a presynaptic neurotransmitter. Within 1 hour of the bite, the clinical effects of black widow spider envenomation (BWSE) include sharp pain, muscle spasm, weakness, tremor, severe abdominal pain with rigidity, hypertension, respiratory distress, diaphoresis, and facial swelling. Priapism has been reported in pediatric patients following BWSE (Hoover, 2004; Quan, 2009).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark RF, \"The Safety and Efficacy of Antivenin",
"      <i>",
"       Latrodectus mactans",
"      </i>",
"      ,\"",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2001, 39(2):125-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/11407497/pubmed\" id=\"11407497\" target=\"_blank\">",
"        11407497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark RF, Wethern-Kestner S, Vance MV, et al, \"Clinical Presentation and Treatment of Black Widow Spider Envenomation: A Review of 163 Cases,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1992, 21(7):782-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/1351707/pubmed\" id=\"1351707\" target=\"_blank\">",
"        1351707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diaz JH, \"The Global Epidemiology, Syndromic Classification, Management, and Prevention of Spider Bites,\"",
"      <i>",
"       Am J Trop Med Hyg",
"      </i>",
"      , 2004, 71(2):239-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/15306718/pubmed\" id=\"15306718\" target=\"_blank\">",
"        15306718",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edberg AL, Lanphear JR, Riley BD, et al, &ldquo;Toxic Traveler? Latrodectus Species Envenomation in Michigan With Refractory Symptoms After Antivenin Administration,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2009, 47(4):356-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/19274505/pubmed\" id=\"19274505\" target=\"_blank\">",
"        19274505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handel CC, Izquierdo LA, and Curet LB, &ldquo;Black Widow Spider (",
"      <i>",
"       Latrodectus mactans",
"      </i>",
"      ) Bite During Pregnancy,&rdquo;",
"      <i>",
"       West J Med",
"      </i>",
"      , 1994, 160(3):261-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/8191768/pubmed\" id=\"8191768\" target=\"_blank\">",
"        8191768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoover NG and Fortenberry JD, \"Use of Antivenin to Treat Priapism After a Black Widow Spider Bite,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(1):e128-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/15231985/pubmed\" id=\"15231985\" target=\"_blank\">",
"        15231985",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isbister GK and Fan HW, &ldquo;Spider Bite,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2011, 378(9808):2039-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/21762981/pubmed\" id=\"21762981\" target=\"_blank\">",
"        21762981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Isbister GK, Graudins A, White J, et al, \"Antivenom Treatment in Arachnidism,\"",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2003, 41(3):291-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/12807312/pubmed\" id=\"12807312\" target=\"_blank\">",
"        12807312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monte AA, Bucher-Bartelson B, and Heard KJ, \"A US Perspective of Symptomatic",
"      <i>",
"       Latrodectus spp.",
"      </i>",
"      Envenomation and Treatment: A National Poison Data System Review,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2011, 45(12):1491-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/22116992/pubmed\" id=\"22116992\" target=\"_blank\">",
"        22116992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nordt SP, Clark RF, Lee A, et al, \"Examination of Adverse Events Following Black Widow Antivenom Use in California,\"",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2012, 50(1):70-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/22175789/pubmed\" id=\"22175789\" target=\"_blank\">",
"        22175789",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Offerman SR, Daubert GP, and Clark RF, &ldquo;The Treatment of Black Widow Spider Envenomation With Antivenin",
"      <i>",
"       Latrodectus Mactans",
"      </i>",
"      : A Case Series,&rdquo;",
"      <i>",
"       Permanente J",
"      </i>",
"      , 2011, 15(3):76-81.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Malley GF, Dart RC, and Kuffner EF, \"Successful Treatment of Latrodectism With Antivenin After 90 Hours,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(8):657.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/10049091 /pubmed\" id=\"10049091 \" target=\"_blank\">",
"        10049091",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan D and Ruha AM, \"Priapism Associated With",
"      <i>",
"       Latrodectus mactans",
"      </i>",
"      Envenomation,\"",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 2009, 27(6):759, e1-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/19751653/pubmed\" id=\"19751653\" target=\"_blank\">",
"        19751653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rojnuckarin P, &ldquo;Antivenom Skin Test: Theory Versus Practice,&rdquo;",
"      <i>",
"       Acta Tropica",
"      </i>",
"      , 2009, 109(1):86.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russel FE, Marcus P, and Streng JA, &ldquo;Black Widow Spider Envenomation During Pregnancy: Report of a Case,&rdquo;",
"      <i>",
"       Toxicon",
"      </i>",
"      , 1979, 17(2):188-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/442109/pubmed\" id=\"442109\" target=\"_blank\">",
"        442109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saucier JR, &ldquo;Arachnid Envenomation,&rdquo;",
"      <i>",
"       Emerg Med Clin North Am",
"      </i>",
"      , 2004, 22(2):405-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/15163574/pubmed\" id=\"15163574\" target=\"_blank\">",
"        15163574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sherman RP, Groll JM, Gonzalez DI, et al, &ldquo;Black Widow Spider (",
"      <i>",
"       Latrodectus mactans",
"      </i>",
"      ) Envenomation in a Term Pregnancy,&rdquo;",
"      <i>",
"       Curr Surg",
"      </i>",
"      , 2000, 57(4):346-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/23/43381/abstract-text/11024247/pubmed\" id=\"11024247\" target=\"_blank\">",
"        11024247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, &ldquo;Guidelines for the Clinical Management of Snake Bites in the South-East Asia Region,&rdquo; 2005, World Health Organization, Geneva. Available at  file://www.searo.who.int/LinkFiles/SDE_mgmt_snake-bite.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12889 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-18D72DAC39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43381=[""].join("\n");
var outline_f42_23_43381=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045279\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045274\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136027\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136014\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045282\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045276\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045281\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136053\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045273\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298765\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218053\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136022\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136033\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045278\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045272\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045284\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225744\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045286\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12889\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12889|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/12/31941?source=related_link\">",
"      Black widow spider (Latrodectus mactans) antivenom: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/36/21059?source=related_link\">",
"      Black widow spider (Latrodectus mactans) antivenom: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_23_43382="Pyogenic granuloma multiple";
var content_f42_23_43382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Multiple pyogenic granulomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43382=[""].join("\n");
var outline_f42_23_43382=null;
var title_f42_23_43383="Invasive Propionibacterium infections";
var content_f42_23_43383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Invasive Propionibacterium infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43383/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43383/contributors\">",
"     Zeina A Kanafani, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43383/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43383/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43383/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43383/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/23/43383/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Propionibacteria are part of the normal flora of human skin and mucosal surfaces. Occasionally, they cause clinically significant infections, particularly in the setting of shoulder surgery, orthopedic hardware, endovascular devices, and cerebrospinal shunts. It can be difficult to determine whether positive culture results for Propionibacteria reflect contamination or true infection.",
"   </p>",
"   <p>",
"    Infections with Propionibacterium species can be classified into three categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acne in teenagers and young adults (when caused by P. acnes)",
"     </li>",
"     <li>",
"      Surgical wound infections",
"     </li>",
"     <li>",
"      Invasive deep seated infections, usually in the setting of implantable devices (eg, pacemakers, shunts, etc)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This card discusses the clinical manifestations, diagnosis, and treatment of invasive Propionibacterium infections in patients with implantable devices. Issues related to acne are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39370?source=see_link\">",
"     \"Treatment of acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Propionibacteria are normally present on human skin and in sebaceous glands and hair follicles; they can also be recovered from the conjunctiva, external ear, nasopharynx, oral cavity, and genitourinary tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, P. acnes is a common environmental surface contaminant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Therefore, it is often difficult to determine whether positive culture results for Propionibacteria reflect contamination or true infection.",
"   </p>",
"   <p>",
"    Propionibacterium species are members of the Actinobacteria class of microorganisms. They are slow-growing, gram-positive, non-motile, anaerobic bacilli of relatively low virulence. The organisms can occur singly, in pairs, or in groups. They produce lactic, propionic, and acetic acids, and unlike most other anaerobic gram-positive bacilli, they are catalase-positive. These organisms may be difficult to identify initially because of their slow growth, especially in clinical specimens that also contain other common, readily recovered organisms. Therefore, identification of Propionibacteria may be overlooked if cultures are not rechecked or if cultures are discarded after three to five days of incubation.",
"   </p>",
"   <p>",
"    Propionibacteria are more likely to represent true pathogens if they are isolated in pure culture from multiple specimens (particularly in the setting of consistent Gram stain morphology between specimens), or from a deep intraoperative specimen. Most clinical infections due to this species are due to P. acnes; other less common species of possible clinical significance include P. granulosum, P. avidum, and P. propionicum. However, most laboratories do not routinely speciate Propionibacterial species. Clinical suspicion for infection should prompt request for speciation of the organism if available from a local microbiology laboratory and if the significance of an isolate is questionable.",
"   </p>",
"   <p>",
"    P. acnes is of relatively low virulence, but is capable of adherence and biofilm formation; this characteristic plays an important role in pathogenesis of infection due to this organism. In the majority of patients with Propionibacterium prosthetic joint infections, infiltration of the glycocalyx with adherence to the implant surface has been observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In one report P. acnes was associated with chronic low-grade infection of implanted biomaterials as frequently as Staphylococcus spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Propionibacterium infections are usually characterized by a paucity of classical symptoms of infection or inflammation. Invasive Propionibacterium infection typically occurs in the setting of prior surgery. Given the low virulence of Propionibacteria, infections with these organisms are usually indolent. In some cases clinical manifestations may be delayed for months and, rarely, for years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    P. acnes tends to inhabit the deep crevices of the skin where surgical antiseptic solutions may penetrate poorly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Flushing the wound during surgery may facilitate transmission of the organism from the surrounding skin into the wound.",
"   </p>",
"   <p>",
"    The ability of P. acnes to adhere and form biofilm facilitates development of infection in patients with surgically implanted foreign material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/4,8-17\">",
"     4,8-17",
"    </a>",
"    ]. Propionibacterium species have been implicated in a variety of serious infections related to implantable devices:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Orthopedic implants (including prosthetic joints as well as spinal hardware) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/10,11,18\">",
"       10,11,18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Endovascular devices (including prosthetic valves and pacemakers) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Central nervous system devices (including shunts, reservoirs, and drains) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/21-24\">",
"       21-24",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infection may present with evidence of device malfunction; in some circumstances, infection is detected at the time of removal of a malfunctioning device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Orthopedic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most orthopedic Propionibacterium infections develop within the first two years after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/10-12,18,25\">",
"     10-12,18,25",
"    </a>",
"    ]. Early infections present with local and systemic inflammatory signs and symptoms (joint effusion, fever, sinus tract formation with purulent discharge) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/11\">",
"     11",
"    </a>",
"    ]. In late presentations these findings may be absent; in such cases manifestations may include pain, joint stiffness, or prosthesis dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients who developed loosened prostheses &ge;2 years after implantation have positive cultures with Propionibacterium species when the hardware is removed. In such cases it may be impossible to determine if the positive cultures represent true infection or contamination secondary to the removal and processing of samples for culture.",
"   </p>",
"   <p>",
"    Risk factors for P. acnes orthopedic infection include prolonged surgery, multiple surgeries, and male gender [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/2,7,12\">",
"     2,7,12",
"    </a>",
"    ]. In a retrospective analysis of 52 cases of P. acnes bone or joint infections, 71 percent of cases occurred in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/10,11,27\">",
"     10,11,27",
"    </a>",
"    ]. Men may be at increased risk for Propionibacteria infection because they have more sebaceous glands and hair follicles than women.",
"   </p>",
"   <p>",
"    Propionibacteria have been implicated in a variety of orthopedic infections, including prosthetic joint infection (3.6 to 5.7 percent of cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/10,28\">",
"     10,28",
"    </a>",
"    ], native joint infection following arthroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/17\">",
"     17",
"    </a>",
"    ], and vertebral osteomyelitis following spine surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/18,25,29-32\">",
"     18,25,29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Propionibacteria appears to have greater predilection for infection involving the shoulder joint than other joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/7,17,33\">",
"     7,17,33",
"    </a>",
"    ]. This may be related to the observation that P. acnes colonization rates for the shoulder appear to be greater than colonization of the knee or hip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/34\">",
"     34",
"    </a>",
"    ]. A peculiar bruising appearance along the surgical incision should raise suspicion for Propionibacterium infection of shoulder prostheses (",
"    <a class=\"graphic graphic_picture graphicRef56978 \" href=\"mobipreview.htm?8/0/8192\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endovascular infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Propionibacterium may cause infections of endovascular devices such as prosthetic valves and pacemakers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one series of 15 cases of Propionibacterium endocarditis, 13 patients had a prosthetic valve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/19\">",
"     19",
"    </a>",
"    ]. The mean onset of infection was 4 years following surgery. Central nervous system emboli, congestive heart failure, cardiac abscess and valve dehiscence may complicate such infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late-onset prosthetic valve infections due to Propionibacterium may be difficult to diagnose, as clinical manifestations may be limited to valve dysfunction with few symptoms suggestive of infection. Furthermore, histological examination of excised paravalvular tissues in such cases may demonstrate minimal evidence of acute inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Central nervous system device infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;P. acnes is a well-known cause of cerebrospinal fluid (CSF) shunt infections. In a retrospective analysis of 78 cases, P. acnes was the third most common causative organism following coagulase-negative staphylococci and S. aureus, even though it only caused 8 percent of all infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When compared with patients with shunt infections due to other organisms, patients with Propionibacterium shunt infections were older and more often had low body temperature, few CSF leukocytes, and high",
"    <span class=\"nowrap\">",
"     CSF/blood",
"    </span>",
"    glucose ratios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition, in contrast to infections due to other common organisms, Propionibacterium shunt infections in children have been associated with CSF eosinophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Propionibacteria have also been implicated in other serious infections such as brain abscess, subdural empyema, sinusitis, peritonitis, and respiratory infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/19,40-44\">",
"     19,40-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Propionibacterium infection frequently poses a diagnostic challenge because it is often difficult to discern whether isolation of Propionibacterium from clinical specimens represents true infection or contamination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/45\">",
"     45",
"    </a>",
"    ]. Growth of Propionibacterium species in superficial specimens and isolation with other skin flora such as coagulase negative staphylococci usually suggest contamination. In some cases delayed growth of Propionibacterium may lead to false-negative results. Thus, when cultures are negative and the clinical suspicion of infection is high, prolonged specimen incubation should be requested (at least seven days).",
"   </p>",
"   <p>",
"    Propionibacterium infection should be considered in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following Propionibacterium isolation from the joint or wound of a patient with signs of postoperative infection following shoulder surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a patient with a prosthetic joint and chronic joint pain in whom there are other clinical signs of joint infection (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42680?source=see_link\">",
"       \"Clinical manifestations and diagnosis of prosthetic joint infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      In a patient with a central nervous system shunt, signs compatible with shunt infection and CNS eosinophilia",
"     </li>",
"     <li>",
"      In a patient with prosthetic valve dysfunction and findings compatible with endocarditis (such as a vegetation or a valve ring abnormality) even when other classical signs of endocarditis such as fever are absent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Microbiological criteria proposed for the diagnosis of prosthetic joint infections due to Propionibacteria include &ge;3 operative cultures (out of five to six specimens) growing biochemically and microbiologically identical organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/12,46\">",
"     12,46",
"    </a>",
"    ]. Other measures that may increase the sensitivity and specificity of intraoperative cultures include sonication of removed implants and prolonged incubation period of culture specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/10,28,47\">",
"     10,28,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hardware removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the role of biofilm formation in the pathogenesis of Propionibacterium infections associated with orthopedic hardware or other implanted devices, device removal is often required in order to achieve cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Often, such infections are associated with evidence of device malfunction; in other circumstances, infection is detected at the time of removal of a malfunctioning device.",
"   </p>",
"   <p>",
"    In a series of 52 patients with orthopedic implant infections due to Propionibacteria, all patients undergoing partial hardware removal had clinical failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/11\">",
"     11",
"    </a>",
"    ]. Complete removal of prosthetic material is particularly important in the setting of device dysfunction, delayed onset infection and chronic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Spinal hardware infection should prompt removal of all components when feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/18,25,31\">",
"     18,25,31",
"    </a>",
"    ]. The decision to remove prosthetic material must be made in the context of individual patient circumstances.",
"   </p>",
"   <p>",
"    In the setting of prosthetic valve endocarditis due to Propionibacterium, valve replacement is frequently necessary, particularly in the setting of congestive heart failure, cardiac abscess, or valve dehiscence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/19,35\">",
"     19,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3591?source=see_link&amp;anchor=H3#H3\">",
"     \"Surgery for prosthetic valve endocarditis\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to hardware removal in the setting of central nervous system device infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44552?source=see_link&amp;anchor=H12#H12\">",
"     \"Infections of central nervous system shunts and other devices\", section on 'Device removal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to antibiotic therapy should be guided by antimicrobial susceptibility. Treatment should be individualized depending on the clinical circumstances. The choice, duration, and route of antimicrobial therapy depend on the site of infection.",
"   </p>",
"   <p>",
"    Propionibacterium isolates are usually highly susceptible to penicillins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , cephalosporins, and carbapenems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/48\">",
"     48",
"    </a>",
"    ]. Most Propionibacterium species are also susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/49\">",
"     49",
"    </a>",
"    ], tetracyclines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/50\">",
"     50",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/5\">",
"     5",
"    </a>",
"    ], macrolides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/50\">",
"     50",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/4\">",
"     4",
"    </a>",
"    ], but resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/48\">",
"     48",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    has also been used for successful treatment of Propionibacterium osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibiotic-resistant P. acnes strains have been recovered from the skin of patients with moderate to severe acne (37 percent of antibiotic-treated patients versus 13 percent of non-treated patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/52\">",
"     52",
"    </a>",
"    ]. Among 304 P. acnes isolates collected from various human infections, 17 percent of isolates were resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and 15 percent to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/53\">",
"     53",
"    </a>",
"    ]. P. acnes isolates embedded in biofilms demonstrate greater resistance than those in the planktonic phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/4\">",
"     4",
"    </a>",
"    ]. In an in vitro model of P. acnes biofilm, biofilm was successfully eradicated by penicillin and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"      linezolid",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"      rifampin",
"     </a>",
"    </span>",
"    (14 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Susceptibility testing for Propionibacterium species is not performed routinely in all laboratories. Therefore, clinicians may have to rely on the local epidemiology; suspicion for resistance should be increased in patients with history of antibiotic treatment for acne.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Orthopedic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management should consist of parenteral therapy; penicillin is the drug of choice based on in vitro susceptibility data. The optimal duration is uncertain and in various reports has ranged from two weeks to several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/10-12,25,27,54\">",
"     10-12,25,27,54",
"    </a>",
"    ]. If, upon transition from acute to long-term care, the administration of penicillin is not practical, reasonable alternatives include cephalosporins such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In the setting of clinical improvement following an initial course of parenteral therapy (minimum two weeks), treatment may be continued with oral antibiotics (minimum two weeks).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    have excellent oral bioavailability and high concentrations in bone tissue; oral beta lactam agents are also appropriate choices. If the prosthesis is retained (eg, because removal of hardware is not feasible), long-term oral suppressive therapy may be warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The assessment of treatment response can be difficult in the absence of inflammatory signs (including elevated erythrocyte sedimentation rate) and other overt symptoms of infection. Important indicators of treatment failure include recurrent joint pain or prostheses dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral penicillin is the drug of choice for treatment of Propionibacterium endocarditis based on in vitro susceptibility data and case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/19,35\">",
"     19,35",
"    </a>",
"    ]. Other options include cephalosporins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    , although clinical data are scarce. Prosthetic valve endocarditis should be treated with parenteral antibiotics for 6 weeks. In addition, many of the reported cases of PVE due this organism have required surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43383/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34712?source=see_link&amp;anchor=H2#H2\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\", section on 'General principles'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Central nervous system device infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should include an agent with good CSF penetration such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    . Device removal coupled with parenteral therapy (10 to 14 days) is usually appropriate. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44552?source=see_link&amp;anchor=H11#H11\">",
"     \"Infections of central nervous system shunts and other devices\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Propionibacteria are part of the normal flora of human skin and mucosal surfaces but can cause clinically significant infection in some circumstances, particularly in the setting of shoulder surgery, orthopedic hardware, endovascular devices, and cerebrospinal shunts. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, Propionibacteria are not usually pathogenic. Therefore it can be difficult to determine whether positive culture results for Propionibacteria reflect contamination or true infection. Propionibacteria are more likely to represent a true pathogen if isolated in pure culture from multiple specimens (particularly when the morphology on Gram stain is consistent), or from a deep intraoperative specimen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology and pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Propionibacteria are of relatively low virulence but capable of adherence and biofilm formation; this characteristic plays an important role in the pathogenesis of infection due to this organism. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Propionibacterium infections are usually indolent and clinical manifestations may be delayed for months or, rarely, years. In addition, Propionibacterium infections are usually characterized by a paucity of classical symptoms of infection or inflammation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the role of biofilm formation in the pathogenesis of Propionibacterium infection, eradication of Propionibacterium infections is difficult without device removal. We suggest hardware removal except when this intervention would result in joint or spine instability (in the case of orthopedic infections), or when the overall condition of the patient makes the procedure unsafe (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hardware removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice and duration of antibiotic therapy should be individualized depending on the clinical circumstances. In general, we suggest parenteral penicillin for initial management of invasive Propionibacterium infections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/1\">",
"      Brook I, Frazier EH. Infections caused by Propionibacterium species. Rev Infect Dis 1991; 13:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/2\">",
"      Berthelot P, Carricajo A, Aubert G, et al. Outbreak of postoperative shoulder arthritis due to Propionibacterium acnes infection in nondebilitated patients. Infect Control Hosp Epidemiol 2006; 27:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/3\">",
"      S&oslash;rensen P, Ejlertsen T, Aaen D, Poulsen K. Bacterial contamination of surgeons gloves during shunt insertion: a pilot study. Br J Neurosurg 2008; 22:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/4\">",
"      Ramage G, Tunney MM, Patrick S, et al. Formation of Propionibacterium acnes biofilms on orthopaedic biomaterials and their susceptibility to antimicrobials. Biomaterials 2003; 24:3221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/5\">",
"      Bayston R, Nuradeen B, Ashraf W, Freeman BJ. Antibiotics for the eradication of Propionibacterium acnes biofilms in surgical infection. J Antimicrob Chemother 2007; 60:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/6\">",
"      Tunney MM, Patrick S, Curran MD, et al. Detection of prosthetic hip infection at revision arthroplasty by immunofluorescence microscopy and PCR amplification of the bacterial 16S rRNA gene. J Clin Microbiol 1999; 37:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/7\">",
"      Kanafani ZA, Sexton DJ, Pien BC, et al. Postoperative joint infections due to Propionibacterium species: a case-control study. Clin Infect Dis 2009; 49:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/8\">",
"      Carricajo A, Nuti C, Aubert E, et al. Propionibacterium acnes contamination in lumbar disc surgery. J Hosp Infect 2007; 66:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/9\">",
"      McLorinan GC, Glenn JV, McMullan MG, Patrick S. Propionibacterium acnes wound contamination at the time of spinal surgery. Clin Orthop Relat Res 2005; :67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/10\">",
"      Levy PY, Fenollar F, Stein A, et al. Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity. Clin Infect Dis 2008; 46:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/11\">",
"      Lutz MF, Berthelot P, Fresard A, et al. Arthroplastic and osteosynthetic infections due to Propionibacterium acnes: a retrospective study of 52 cases, 1995-2002. Eur J Clin Microbiol Infect Dis 2005; 24:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/12\">",
"      Zeller V, Ghorbani A, Strady C, et al. Propionibacterium acnes: an agent of prosthetic joint infection and colonization. J Infect 2007; 55:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/13\">",
"      Sperling JW, Kozak TK, Hanssen AD, Cofield RH. Infection after shoulder arthroplasty. Clin Orthop Relat Res 2001; :206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/14\">",
"      Topolski MS, Chin PY, Sperling JW, Cofield RH. Revision shoulder arthroplasty with positive intraoperative cultures: the value of preoperative studies and intraoperative histology. J Shoulder Elbow Surg 2006; 15:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/15\">",
"      Launder WJ, Hungerford DS. Late infection of total hip arthroplasty with Propionibacterium acnes: a case and review of the literature. Clin Orthop Relat Res 1981; :170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/16\">",
"      Stoll T, Stucki G, Br&uuml;hlmann P, et al. Infection of a total knee joint prosthesis by peptostreptococcus micros and propionibacterium acnes in an elderly RA patient: implant salvage with longterm antibiotics and needle aspiration/irrigation. Clin Rheumatol 1996; 15:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/17\">",
"      Athwal GS, Sperling JW, Rispoli DM, Cofield RH. Deep infection after rotator cuff repair. J Shoulder Elbow Surg 2007; 16:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/18\">",
"      Hahn F, Zbinden R, Min K. Late implant infections caused by Propionibacterium acnes in scoliosis surgery. Eur Spine J 2005; 14:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/19\">",
"      Lalani T, Person AK, Hedayati SS, et al. Propionibacterium endocarditis: a case series from the International Collaboration on Endocarditis Merged Database and Prospective Cohort Study. Scand J Infect Dis 2007; 39:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/20\">",
"      Zedtwitz-Liebenstein K, Gabriel H, Graninger W. Pacemaker endocarditis due to Propionibacterium acnes. Infection 2003; 31:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/21\">",
"      Viraraghavan R, Jantausch B, Campos J. Late-onset central nervous system shunt infections with Propionibacterium acnes: diagnosis and management. Clin Pediatr (Phila) 2004; 43:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/22\">",
"      Thompson TP, Albright AL. Propionibacterium [correction of Proprionibacterium] acnes infections of cerebrospinal fluid shunts. Childs Nerv Syst 1998; 14:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/23\">",
"      Lishner M, Perrin RG, Feld R, et al. Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. Arch Intern Med 1990; 150:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/24\">",
"      Desai A, Lollis SS, Missios S, et al. How long should cerebrospinal fluid cultures be held to detect shunt infections? Clinical article. J Neurosurg Pediatr 2009; 4:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/25\">",
"      Richards BR, Emara KM. Delayed infections after posterior TSRH spinal instrumentation for idiopathic scoliosis: revisited. Spine (Phila Pa 1976) 2001; 26:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/26\">",
"      Schneeberger AG, Gilbart MK, Sheikh R, et al. Non-purulent low-grade infection as cause of pain following shoulder surgery: preliminary results. Chir Organi Mov 2009; 93 Suppl 1:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/27\">",
"      Noble RC, Overman SB. Propionibacterium acnes osteomyelitis: case report and review of the literature. J Clin Microbiol 1987; 25:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/28\">",
"      Zappe B, Graf S, Ochsner PE, et al. Propionibacterium spp. in prosthetic joint infections: a diagnostic challenge. Arch Orthop Trauma Surg 2008; 128:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/29\">",
"      Harris AE, Hennicke C, Byers K, Welch WC. Postoperative discitis due to Propionibacterium acnes: a case report and review of the literature. Surg Neurol 2005; 63:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/30\">",
"      Richards BS. Delayed infections following posterior spinal instrumentation for the treatment of idiopathic scoliosis. J Bone Joint Surg Am 1995; 77:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/31\">",
"      Collins I, Wilson-MacDonald J, Chami G, et al. The diagnosis and management of infection following instrumented spinal fusion. Eur Spine J 2008; 17:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/32\">",
"      Saeed MU, Mariani P, Martin C, et al. Anaerobic spondylodiscitis: case series and systematic review. South Med J 2005; 98:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/33\">",
"      Kelly JD 2nd, Hobgood ER. Positive culture rate in revision shoulder arthroplasty. Clin Orthop Relat Res 2009; 467:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/34\">",
"      Patel A, Calfee RP, Plante M, et al. Propionibacterium acnes colonization of the human shoulder. J Shoulder Elbow Surg 2009; 18:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/35\">",
"      Sohail MR, Gray AL, Baddour LM, et al. Infective endocarditis due to Propionibacterium species. Clin Microbiol Infect 2009; 15:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/36\">",
"      Gu&iacute;o L, Sarri&aacute; C, de las Cuevas C, et al. Chronic prosthetic valve endocarditis due to Propionibacterium acnes: an unexpected cause of prosthetic valve dysfunction. Rev Esp Cardiol 2009; 62:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/37\">",
"      Conen A, Walti LN, Merlo A, et al. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis 2008; 47:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/38\">",
"      Arnell K, Cesarini K, Lagerqvist-Widh A, et al. Cerebrospinal fluid shunt infections in children over a 13-year period: anaerobic cultures and comparison of clinical signs of infection with Propionibacterium acnes and with other bacteria. J Neurosurg Pediatr 2008; 1:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/39\">",
"      Fulkerson DH, Boaz JC. Cerebrospinal fluid eosinophilia in children with ventricular shunts. J Neurosurg Pediatr 2008; 1:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/40\">",
"      Barazi SA, Gnanalingham KK, Chopra I, van Dellen JR. Delayed postoperative intracerebral abscess caused by Proprionibacterium acnes: case report and review of the literature. Br J Neurosurg 2003; 17:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/41\">",
"      Critchley G, Strachan R. Postoperative subdural empyema caused by Propionibacterium acnes--a report of two cases. Br J Neurosurg 1996; 10:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/42\">",
"      Claeys G, Verschraegen G, De Potter C, et al. Bronchopneumonia caused by Propionibacterium acnes. Eur J Clin Microbiol Infect Dis 1994; 13:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/43\">",
"      Niederfuhr A, Kirsche H, Riechelmann H, Wellinghausen N. The bacteriology of chronic rhinosinusitis with and without nasal polyps. Arch Otolaryngol Head Neck Surg 2009; 135:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/44\">",
"      Castillo AA, Lew SQ, Smith AM, et al. Peritoneal dialysis-associated peritonitis caused by Propionibacteria species. Am J Kidney Dis 1999; 33:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/45\">",
"      Dramis A, Aldlyami E, Grimer RJ, et al. What is the significance of a positive Propionibacterium acnes culture around a joint replacement? Int Orthop 2009; 33:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/46\">",
"      Atkins BL, Athanasou N, Deeks JJ, et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty. The OSIRIS Collaborative Study Group. J Clin Microbiol 1998; 36:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/47\">",
"      Tunney MM, Patrick S, Gorman SP, et al. Improved detection of infection in hip replacements. A currently underestimated problem. J Bone Joint Surg Br 1998; 80:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/48\">",
"      Roberts SA, Shore KP, Paviour SD, et al. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003. J Antimicrob Chemother 2006; 57:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/49\">",
"      Tyrrell KL, Citron DM, Warren YA, et al. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob Agents Chemother 2006; 50:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/50\">",
"      G&uuml;belin W, Mart&iacute;nez MA, Molina MT, et al. Antimicrobial susceptibility of strains of Propionibacterium acnes isolated from inflammatory acne. Rev Latinoam Microbiol 2006; 48:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/51\">",
"      Ghosh M, Talwani R, Gilliam BL. Propionibacterium skull osteomyelitis treated with daptomycin. Clin Neurol Neurosurg 2009; 111:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/52\">",
"      Oprica C, Emtestam L, Lapins J, et al. Antibiotic-resistant Propionibacterium acnes on the skin of patients with moderate to severe acne in Stockholm. Anaerobe 2004; 10:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/53\">",
"      Oprica C, Nord CE, ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin Microbiol Infect 2005; 11:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/54\">",
"      Marculescu CE, Berbari EF, Hanssen AD, et al. Prosthetic joint infection diagnosed postoperatively by intraoperative culture. Clin Orthop Relat Res 2005; 439:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43383/abstract/55\">",
"      Clayton JJ, Baig W, Reynolds GW, Sandoe JA. Endocarditis caused by Propionibacterium species: a report of three cases and a review of clinical features and diagnostic difficulties. J Med Microbiol 2006; 55:981.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5538 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43383=[""].join("\n");
var outline_f42_23_43383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Orthopedic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endovascular infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Central nervous system device infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hardware removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Orthopedic infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Central nervous system device infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5538|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/0/8192\" title=\"picture 1\">",
"      Propionibacterium shoulder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42680?source=related_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44552?source=related_link\">",
"      Infections of central nervous system shunts and other devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3591?source=related_link\">",
"      Surgery for prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39370?source=related_link\">",
"      Treatment of acne vulgaris",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_23_43384="Procedural sedation in children outside of the operating room";
var content_f42_23_43384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Procedural sedation in children outside of the operating room",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43384/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43384/contributors\">",
"     Deborah C Hsu, MD, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43384/contributors\">",
"     Joseph P Cravero, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43384/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43384/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43384/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43384/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43384/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/23/43384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of diagnostic and therapeutic procedures in children is safer and more likely to be successful when the patient does not move and when any associated pain and anxiety are effectively controlled. Pharmacologic and nonpharmacologic interventions that consider the child's developmental status and the clinical circumstances are often required to meet these goals. In addition, attention to the treatment of pain and anxiety associated with the child's condition is a requisite of acceptable and compassionate patient care. Specific issues related to the importance of addressing pain and anxiety in emergency medical systems has been emphasized in a clinical report from the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased availability of short-acting sedatives along with accurate noninvasive monitoring and improved sedation training programs has enabled effective and safe management of sedation and analgesia outside the operating room [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/2\">",
"     2",
"    </a>",
"    ]. Procedural sedation is an evolving field practiced by a diverse group of practitioners in an expanding variety of clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/3\">",
"     3",
"    </a>",
"    ]. Among the challenges that must be addressed are the development of standardized definitions of outcomes, particularly with respect to what constitutes satisfactory sedation and what is an adverse event. In addition there remain a number of guidelines for sedation promulgated by a various specialty societies. Unified guidelines would encourage consistent care across specialties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the indications, contraindications, and steps for safe performance of procedural sedation in children undergoing diagnostic or therapeutic procedures, regardless of setting.",
"   </p>",
"   <p>",
"    Pre-sedation evaluation, preparation for procedural sedation, properties of specific agents used for pediatric procedural sedation, strategies for selecting medications for pediatric procedural sedation, pediatric airway management, and sedation in adults are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link\">",
"       \"Preparation for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=see_link\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link\">",
"       \"Selection of medications for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"       \"Procedural sedation in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GOALS OF SEDATION AND ANALGESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goals of sedation and analgesia for painful procedures are to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintain patient safety and welfare",
"     </li>",
"     <li>",
"      Minimize physical pain and discomfort",
"     </li>",
"     <li>",
"      Control anxiety, minimize psychological trauma, maximize amnesia",
"     </li>",
"     <li>",
"      Control behavior and movement to allow safe performance of procedures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician must determine the appropriate level of sedation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    analgesia required for a particular procedure. In addition to medications, non-pharmacological interventions, such as verbal reassurance, distraction techniques, and hypnosis may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1684879\">",
"     'Nonpharmacologic interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts to codify sedation &ldquo;states&rdquo; have evolved over the last 30 years. The American Academy of Pediatrics, the American Society of Anesthesiologists, the American Academy of Pediatric Dentists, and the Joint Commission use the following definitions to describe the depth of sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/3,5,9\">",
"     3,5,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Analgesia",
"      </strong>",
"      &ndash; Relief of pain without intentionally producing a sedated state. Altered mental status may be a secondary effect of medications administered for analgesia.",
"     </li>",
"     <li>",
"      <strong>",
"       Minimal sedation",
"      </strong>",
"      &ndash; The patient responds normally to verbal commands. Cognitive function and coordination may be impaired, but ventilatory and cardiovascular function is unaffected.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate",
"       <span class=\"nowrap\">",
"        sedation/analgesia",
"       </span>",
"      </strong>",
"      &ndash; The patient has depression of consciousness but can respond purposefully to verbal commands either alone or accompanied by light touch. Maintains airway and adequate ventilation without intervention. Cardiovascular function is maintained.",
"     </li>",
"     <li>",
"      <strong>",
"       Deep",
"       <span class=\"nowrap\">",
"        sedation/analgesia",
"       </span>",
"      </strong>",
"      &ndash; The patient cannot be easily aroused but responds purposefully to noxious stimulation. May require assistance to maintain airway and adequate ventilation. Cardiovascular function is usually maintained.",
"     </li>",
"     <li>",
"      <strong>",
"       General anesthesia",
"      </strong>",
"      &ndash; The patient cannot be aroused. Often requires assistance to maintain airway and positive pressure ventilation. Cardiovascular function may be impaired.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines and regulatory agencies also use these sedation depth descriptions to describe the relative risk state for a given patient, thus the level of provider care and monitoring varies with the sedation level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/3\">",
"     3",
"    </a>",
"    ]. As a general rule, the Joint Commission recommends that providers have the capability of managing patients one level deeper than the target depth. The progression from mild sedation to general anesthesia is a continuum and patients can easily move from one &ldquo;level&rdquo; of sedation to another. Patient response to sedation is highly variable, with some patients becoming deeply sedated after minimal doses and others requiring much higher doses. In addition, differentiation of these levels of sedation may be difficult or impossible during a given test or procedure for a given patient.",
"   </p>",
"   <p>",
"    Members of the American College of Emergency Physicians have suggested the following definition for sedation induced by",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dissociative sedation",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      sedation is characterized by a dissociative trance-like, cataleptic state in which the patient experiences profound analgesia and amnesia, but retains airway protective reflexes, spontaneous respirations, and cardiopulmonary stability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts have suggested that this state should be considered distinct from the sedation spectrum outlined above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/10\">",
"     10",
"    </a>",
"    ]. While potentially useful, this categorization of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    sedation is not part of the standard definitions of sedation in other medical specialties or regulatory bodies described above. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=see_link&amp;anchor=H2152498#H2152498\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\", section on 'Ketamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the purposes of this article, &ldquo;procedural sedation&rdquo; refers to the broad spectrum of interventions that can be used to alter patient response so that tests and procedures can be accomplished and is not intended as an alternative term for the levels of sedation presented above.",
"   </p>",
"   <p>",
"    &ldquo;Conscious sedation&rdquo; previously referred to a specific sedation state within the levels of sedation presented above. Because effective sedation usually impairs consciousness, this term is no longer used by the American Academy of Pediatrics and the American Society of Anesthesiologists when referring to sedation states.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1683199\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute indications for the performance of procedural sedation in children. It may be used for any procedure in which a child's pain or anxiety may be excessive and movement may impede performance. The need for sedation will vary greatly with a child&rsquo;s developmental or behavioral status. Procedural sedation also facilitates deep relaxation and increases the chances of successful closed reduction of a dislocated joint or displaced fracture.",
"   </p>",
"   <p>",
"    The targeted depth of sedation and the selection of medications largely depend upon the procedure performed, the anticipated degree of pain, and patient factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link\">",
"     \"Selection of medications for pediatric procedural sedation outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The properties of the specific agents with respect to pediatric sedation are listed in the tables and discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=see_link\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Procedures that commonly warrant procedural sedation in children include imaging by computed tomography or magnetic resonance imaging, fracture reduction, complex laceration repair, lumbar puncture, abscess incision and drainage, instrumentation (eg, endoscopy, bronchoscopy), burn dressing change, and chest tube or central line placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1683207\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are",
"    <strong>",
"     no",
"    </strong>",
"    absolute contraindications to procedural sedation in children.",
"   </p>",
"   <p>",
"    Relative contraindications to procedural sedation include signs of a difficult airway or significant medical comorbidities (American Society of Anesthesia Classification III or higher). Those patients with ASA classes III, IV, and V (",
"    <a class=\"graphic graphic_table graphicRef78084 \" href=\"mobipreview.htm?9/5/9307\">",
"     table 3",
"    </a>",
"    ), special needs, or airway abnormalities warrant consultation with a pediatric anesthesiologist or clinician with similar pediatric sedation expertise. A history of severe sleep apnea or airway abnormality is also an important consideration when planning sedation care. Children who readily obstruct their airway when asleep may do so during sedation and are at risk for excessive response to sedative medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link&amp;anchor=H1560699#H1560699\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Risk classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link&amp;anchor=H11046848#H11046848\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Airway assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    True allergic reactions to commonly used sedation medications are rare. However, caregivers may report adverse events with specific classes of agents as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paradoxical reactions (patient becomes more agitated rather than sedated) may occur with benzodiazepines and barbiturates, especially in younger children.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"       Morphine",
"      </a>",
"      administration is associated with histamine release that may produce hives, especially in regions of the body where it is administered.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"       Fentanyl",
"      </a>",
"      is associated with nasal pruritus.",
"     </li>",
"     <li>",
"      Agitation with emergence has been described with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      , barbiturates, and other sedatives.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, prior paradoxical reactions with benzodiazepines or emergence phenomenon after",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    may warrant avoidance of these agents for sedation in individual patients.",
"   </p>",
"   <p>",
"    Procedural sedation should also be avoided in children for whom the risk of sedation outweighs the benefit. The patient&rsquo;s fasting status is a key consideration when assessing this risk. The purpose of fasting prior to sedation is to reduce the risk of pulmonary aspiration of gastric contents. The use of prolonged fasting intervals prior to sedation remains an area of practice difference among clinicians providing sedation and anesthesia for children. Evidence regarding the optimum duration of fasting required to reduce the risk of aspiration during pediatric procedural sedation is limited. Patients with severe gastroesophageal reflux disease and acute or chronic decreased gastrointestinal motility are at higher risk of aspiration and aspiration precautions should be continued at all times. Patients known to have airways that are difficult to intubate, especially if mask ventilation is also difficult, may be challenging to rescue if sedation leads to airway obstruction. Clinicians should use fasting status, aspiration risk, airway difficulty and urgency of the procedure to decide the timing of sedation relative to last oral intake, the target depth of sedation, and the specific medications used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link&amp;anchor=H11047750#H11047750\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Fasting and aspiration risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1683215\">",
"    <span class=\"h1\">",
"     PERFORMING PROCEDURAL SEDATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6090197\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before performing procedural sedation, the clinician should obtain written informed consent from the caregiver. Key components of this consent include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proposed benefits, typically the ability to perform a procedure effectively while minimizing pain, anxiety, and psychological trauma",
"     </li>",
"     <li>",
"      Possible risks, which are often agent specific, but commonly include potential for airway compromise, hypoxia, and vomiting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The consent process should include specific discussion of the drug options and potential routes of administration for procedural sedation as well as alternatives including local or regional anesthesia and, when appropriate, general anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1683014\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparation for procedural sedation in children outside of the operating room is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children undergoing procedural sedation should have assessment of the following (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link&amp;anchor=H1560692#H1560692\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Pre-sedation evaluation'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fasting status",
"     </li>",
"     <li>",
"      Focused medical examination with specific attention to the airway",
"     </li>",
"     <li>",
"      American Society of Anesthesiologists classification",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians who administer sedation must understand the pharmacology of the drugs they use and be comfortable choosing a procedural sedation plan for the patient. Because depression of consciousness is a continuum and responses to medications vary, clinicians must be able to deal with complications in patients whose level of sedation becomes deeper than intended or who experience an adverse reaction to medication. Competence in emergency airway management is mandatory if deep sedation is intended or possible and is strongly advised for lighter levels.",
"   </p>",
"   <p>",
"    Prior to the start of procedural sedation, the clinician should ensure that monitoring devices are present and functioning properly and that oxygen, oxygen delivery devices, suction equipment, pediatric airway equipment, an emergency cart with appropriate medications, and a defibrillator are immediately available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link&amp;anchor=H1560734#H1560734\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Equipment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of sedation requires at least two individuals, typically an advanced practice clinician (eg, physician, physician&rsquo;s assistant, advanced practice registered nurse, nurse anesthetist) and an assistant. In addition to the assistant, it is preferable to have two advanced practice clinicians present (one to administer the sedation, while the other performs the procedure) for moderate to deep sedation, whenever possible. At least one person present should be trained in advanced pediatric life support and be skilled in airway management and cardiopulmonary resuscitation. In any case, there should be a competent individual available to continuously monitor breathing, vital signs, pulse oximetry, and, when available, end-tidal carbon dioxide. This individual should also be tasked to document vital signs, level of consciousness, drug administration, and any complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link&amp;anchor=H1560713#H1560713\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Personnel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link&amp;anchor=H1560720#H1560720\">",
"     \"Preparation for pediatric procedural sedation outside of the operating room\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1683230\">",
"    <span class=\"h2\">",
"     Preoxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant practice variation exists regarding the use of preoxygenation and continuous supplemental oxygenation during procedural sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/11\">",
"     11",
"    </a>",
"    ]. The potential benefits of preoxygenation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maximizing bloodstream oxygenation during procedural sedation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Maximizing lung storage of oxygen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Maintenance of oxygenation during periods of apnea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, continuous supplemental oxygen delays desaturation as measured by pulse oximetry and may delay recognition of apnea unless capnography or direct visualization of chest wall movement occurs continuously throughout sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/14\">",
"     14",
"    </a>",
"    ]. Administration of supplemental oxygen to infants and young children may also increase anxiety prior to sedation. In addition, no evidence has established that preoxygenation or continuous administration of supplemental oxygen in children undergoing procedural sedation is associated with improved safety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If preoxygenation and continuous supplemental oxygen is provided, then the patient should also be monitored with continuous capnography or direct visualization of chest wall movement throughout sedation.",
"   </p>",
"   <p>",
"    The use of oxygen in adults undergoing procedural sedation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"     \"Procedural sedation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link&amp;anchor=H11#H11\">",
"     \"Procedural sedation in adults\", section on 'Monitoring and preoxygenation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1683246\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommended monitoring during procedural sedation includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous visual observation of face, mouth, and chest wall movement when feasible",
"     </li>",
"     <li>",
"      Initial and repeated measures of vital signs",
"     </li>",
"     <li>",
"      Continuous measurement of heart rate and pulse oximetry",
"     </li>",
"     <li>",
"      End tidal carbon dioxide detection, especially when visual observation of breathing is not possible (eg, during magnetic resonance imaging)",
"     </li>",
"     <li>",
"      Repeated blood pressure measurements in patients receiving moderate or deep sedation or agents known to cause hemodynamic instability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications from sedation such as respiratory depression are most likely to occur within 5 to 10 minutes after administration of intravenous medication and immediately after the procedure when stimuli associated with the procedure are removed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, monitoring should be especially close during these periods.",
"   </p>",
"   <p>",
"    Vital signs consisting of heart rate, respirations, and blood pressure should be recorded at specific intervals, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Before starting the procedure",
"     </li>",
"     <li>",
"      After the administration of the sedative agent(s)",
"     </li>",
"     <li>",
"      At completion of the procedure",
"     </li>",
"     <li>",
"      During early recovery",
"     </li>",
"     <li>",
"      At completion of recovery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If deep sedation is used or if a patient has significant underlying illness, vital signs should be measured at least every five minutes. As a practical consideration, unnecessary stimulation, such as inflation of a blood pressure cuff, beginning a painful procedure, or familial separation may hinder the induction of sedation in a young or anxious child. Once a complete set of vital signs has been obtained, the child can be monitored visually until the sedative drugs have begun to take effect. At this point, monitoring of pulse oximetry and heart rate, at a minimum, should be initiated.",
"   </p>",
"   <p>",
"    We suggest that monitoring of children receiving moderate or deep procedural sedation include end-tidal carbon dioxide detection (ETCO2) throughout the procedure and during recovery. ETCO2 monitoring is increasingly available in many settings for nonintubated patients and may be helpful to assess ventilation during sedation and analgesia. Increases in ETCO2 may be detected in patients with respiratory depression before hypoxemia is noted, particularly in those who are receiving supplemental oxygen. ETCO2 is also more sensitive for detecting hypoventilation and apnea than clinical assessment. These findings have been illustrated in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial describing children receiving procedural sedation for endoscopy, ETCO2 monitoring identified alveolar hypoventilation in 56 percent of procedures and apnea during 24 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/16\">",
"       16",
"      </a>",
"      ]. Endoscopy staff observing the patients directly reported poor ventilation in 3 percent of all procedures and identified no apnea. Children who were stimulated after 15 seconds of hypoventilation were significantly less likely to develop arterial oxygen desaturation than those who were stimulated after 60 seconds of hypoventilation.",
"     </li>",
"     <li>",
"      Abnormal ETCO2 levels were observed in 60 percent of patients in a prospective sample of adults and children undergoing procedural sedation in an emergency department. Changes in ETCO2 occurred before oxygen desaturation or observed hypoventilation in 70 percent of subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective observational study describing adults undergoing procedural sedation in an emergency department, 58 percent had respiratory depression, as detected by ETCO2, at a time when they were readily responsive to verbal stimulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these studies suggest that ETCO2 monitoring helps detect hypoventilation in a timely fashion, especially in patients receiving supplemental oxygen, and is an important adjunct to visual observation and pulse oximetry. Having noted these advantages, there are no studies that prove serious adverse events (eg, resuscitation from apnea or hospital admissions) are decreased by the use of ETCO2 monitoring. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=see_link&amp;anchor=H15#H15\">",
"     \"Carbon dioxide monitoring (capnography)\", section on 'Procedural sedation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bispectral index (BIS) is a measure of consciousness obtained by continuous electroencephalographic (EEG) monitoring of probes placed on the forehead. The EEG signal is processed by a proprietary computer algorithm. BIS was derived in adults and is used in some settings to monitor for awareness to anesthesia. It has a range of 0 (no brain activity) to 100 (alert). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=see_link&amp;anchor=H15#H15\">",
"     \"Awareness with recall following general anesthesia\", section on 'Brain monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BIS is of uncertain value in monitoring children during procedural sedation because it varies in its prediction of sedation depth by patient age and sedative agent. As an example, in a combined analysis of four observational studies, BIS was found to differentiate light from moderate or deep sedation in children with reasonable sensitivity (74 to 83 percent) and specificity (78 to 84 percent). However, BIS differentiated moderate from deep sedation with poor sensitivity (58 to 71 percent) and specificity (57 to 66 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/19\">",
"     19",
"    </a>",
"    ]. BIS values in children were lower in infants and patients who received opioids. BIS values did not correlate with sedation depth in children receiving",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    . Thus, BIS is not routinely recommended for monitoring of pediatric sedations outside of the operating room.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1684879\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic interventions include behavioral and cognitive approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. For many children, the use of nonpharmacologic interventions may prevent the need for procedural sedation. In situations where the patient is conscious during the sedation, behavioral and cognitive approaches are complementary to pharmacologic interventions and should be used. These techniques also help to reduce preprocedural agitation which permits an easier transition to sedation, may reduce the amount of medication required for effective sedation, and may decrease the frequency of adverse events, including emergence phenomena. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link&amp;anchor=H6054074#H6054074\">",
"     \"Selection of medications for pediatric procedural sedation outside of the operating room\", section on 'Nonpharmacologic interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Behavioral treatments include the techniques of desensitization, distraction, reinforcing coping skills, positive reinforcement, and relaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Desensitization allows for gradual, increasing exposure to the procedure over a period of time. This technique maintains anxiety at low levels and lessens the learned fear associated with the procedure. For example, children could be exposed to a &ldquo;mock&rdquo; magnetic resonance imaging (MRI) scanner progressively over time to provide desensitization without the expense of reducing the availability of an actual MRI machine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Distraction techniques involve an age appropriate stimulus to use during the procedure, such as non-nutritive sucking in infants, bubble blowing, party blowers, listening to a book, counting, interactive toys, playing music through headphones, video games, and videotapes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/7,21\">",
"       7,21",
"      </a>",
"      ]. In a randomized trial that included 240 children requiring laceration repair in an emergency department, distraction techniques were associated with a significant reduction in situational anxiety among older children and lower parental perception of pain and distress among younger children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Positive reinforcement involves providing patients with positive statements and rewards after undergoing a procedure.",
"     </li>",
"     <li>",
"      Relaxation techniques can be taught to reduce children's anxiety associated with procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parental involvement enhances the impact of behavioral pain management if the parent is properly prepared for a positive role (eg, coached on language to use, taught distraction and coping skills techniques) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/7,23\">",
"     7,23",
"    </a>",
"    ]. In addition, parental anxiety is a predictor of child anxiety. Thus, management of parental anxiety is an important element in allaying a child's fears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cognitive approaches are also used to manage pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/6,23\">",
"     6,23",
"    </a>",
"    ]. Providing the child with information about the procedure before it is started may help allay anxiety. The content of this preparation needs to be age appropriate. Child life programs frequently use \"medical play,\" including exploration of medical equipment and dramatic play enacting clinical situations, to help patients cope with painful treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concrete hypnosis can also be used to help direct the patient's attention away from the procedure, and children can be taught positive statements that they can repeat to themselves when they feel anxious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1535752\">",
"    <span class=\"h2\">",
"     Medication administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of agent and mode of administration vary according to patient factors, the type of procedure performed, and the anticipated degree of pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=see_link\">",
"     \"Selection of medications for pediatric procedural sedation outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Careful titration of the chosen medication is often necessary to safely achieve the desired depth of sedation. The dosing and method of administration for the medications commonly used for procedural sedation in children outside of the operating room are presented in the tables (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ) and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=see_link\">",
"     \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1683339\">",
"    <span class=\"h1\">",
"     DISCHARGE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring should continue until the child meets criteria for safe discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/25\">",
"     25",
"    </a>",
"    ]. These criteria include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airway patency and stable cardiovascular function",
"     </li>",
"     <li>",
"      Easy arousability with intact protective reflexes",
"     </li>",
"     <li>",
"      Ability to talk (if age-appropriate)",
"     </li>",
"     <li>",
"      Ability to sit up unaided (if age-appropriate) and maintain wakefulness",
"     </li>",
"     <li>",
"      Adequate hydration with management of any nausea or vomiting",
"     </li>",
"     <li>",
"      Appropriate management of any continued pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Young infants or children who are handicapped should return to the level of responsiveness observed before sedation. The exact duration of recovery time will vary with the nature of the patient (age, body mass index, etc) and the sedative agent or agents used (",
"    <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"     table 2",
"    </a>",
"    ). Of note, serious adverse effects, including hypoxia, stridor, or hypotension have been described during the recovery phase of procedural sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, close monitoring is required until these discharge criteria are met.",
"   </p>",
"   <p>",
"    Because of the significant risk of apnea after sedation, term infants with postconceptual ages (PCA) &le;45 weeks and former premature infants with PCA &lt;60 weeks should undergo prolonged observation of respiratory status prior to discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/27\">",
"     27",
"    </a>",
"    ]. The minimum duration of observation is derived from post-anesthesia experience in term and pre-term infants and varies depending upon PCA, the medications used, and patient comorbidities (eg, anemia, apnea of prematurity, chronic lung disease, or neurologic disease):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All infants term or pre-term with PCA &le;45 weeks &ndash; 12 hours",
"     </li>",
"     <li>",
"      Pre-term infants with PCA 46 to 60 weeks and significant comorbidities &ndash; 12 hours",
"     </li>",
"     <li>",
"      Healthy pre-term infants with PCA 46 to 60 weeks &ndash; 6 hours (12 hours if given opioids or other medications with significant respiratory depressant effects)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients, who develop apnea during observation, warrant prolonged observation until they are free of apnea for at least 12 hours. In some patients with frequent apneic episodes, caffeine administration may be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43223?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of apnea of prematurity\", section on 'Methylxanthine therapy'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     ADVERSE OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse outcomes associated with procedural sedation for children are unlikely when standardized safe practices are observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/5\">",
"     5",
"    </a>",
"    ]. In a report describing 30,037 prospectively collected hospital-based pediatric",
"    <span class=\"nowrap\">",
"     sedation/anesthesia",
"    </span>",
"    encounters from sedation services at multiple institutions with 77 percent of the sedations performed by anesthesiologists, emergency physicians, or intensivists, the overall incidence of adverse events (primarily transient oxygen desaturation, vomiting, and excessive secretions) was 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/28\">",
"     28",
"    </a>",
"    ]. Laryngospasm and apnea occurred less commonly and there were no deaths. One patient was successfully resuscitated from cardiac arrest. Thus adverse events are relatively common in pediatric procedural sedation, but when personnel rapidly respond and reverse the adverse event, deleterious outcomes are rare.",
"   </p>",
"   <p>",
"    The consequences of an adverse event that is not immediately recognized and treated can be devastating. In one retrospective report describing adverse sedation events in children, the deleterious outcomes of permanent neurologic injury or death was associated with adverse events that occurred in nonhospital-based facilities and with those for which resuscitative efforts were inadequate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/29\">",
"     29",
"    </a>",
"    ]. Other factors that contributed to adverse outcomes were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inadequate and inconsistent physiologic monitoring",
"     </li>",
"     <li>",
"      Inadequate medical evaluation before sedation",
"     </li>",
"     <li>",
"      No independent observer",
"     </li>",
"     <li>",
"      Medication errors",
"     </li>",
"     <li>",
"      Inadequate recovery procedures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse sedation events occur with all routes of administration and classes of medication, including those considered to have minimal effect on breathing. Poor outcomes also have been associated with excessive doses, drug interactions, administration by personnel without medical training, and, after discharge, drugs with long half-lives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited evidence suggests that implementation of hospital-wide guidelines for procedural sedation and analgesia may decrease the incidence of adverse events and adverse outcomes. As an example, hospital-wide implementation of national sedation and analgesia guidelines in one children&rsquo;s hospital resulted in a significant reduction in monthly adverse events during pediatric procedural sedation from 11 to 5 percent over three years (p &lt;0.001) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43384/abstract/31\">",
"     31",
"    </a>",
"    ]. In order to make pediatric procedural sedation as safe as possible, institutions should develop protocols that specify a pre-sedation evaluation, including a sedation plan, monitoring during the procedure and recovery, discharge and follow-up criteria, credentialing for personnel, and a quality improvement monitoring mechanism.",
"   </p>",
"   <p>",
"    Detailed and effective communication between healthcare providers and across services is also essential to the safe practice of procedural sedation. Protocols should include procedures for transferring care of sedated children. Specific information regarding medications received during the sedation with doses, times, and response should be included with the usual details of the medical history, daily medications, allergies and vital signs.",
"   </p>",
"   <p>",
"    Finally, health care providers who perform procedural sedation in children should have strong resuscitation and advanced pediatric life support skills, including advanced training in the assessment and management of the pediatric airway as well as specific training in pediatric procedural sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;Procedural sedation&rdquo; is a term advanced by the American College of Emergency Physicians and used by a variety of practitioners that includes the broad spectrum of interventions that can be used to alter patient response so that tests and procedures can be accomplished. The progression from mild sedation to general anesthesia is a continuum and patients can easily move from one &ldquo;level&rdquo; of sedation to another. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no absolute indications for the performance of procedural sedation in children. It may be used for any procedure in which a child's pain or anxiety may be excessive and movement may impede performance. The need for sedation will vary greatly with a child&rsquo;s developmental or behavioral status. (See",
"      <a class=\"local\" href=\"#H1683199\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The necessary preparation for safely performing procedural sedation in children is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=see_link\">",
"       \"Preparation for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The properties of the specific agents with respect to pediatric sedation are listed in the tables and discussed in detail separately (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=see_link\">",
"       \"Pharmacologic agents for pediatric procedural sedation outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Relative contraindications to procedural sedation include signs of a difficult airway or significant medical comorbidities (American Society of Anesthesiologists Classification III or higher). Those patients with ASA classes III, IV, and V (",
"      <a class=\"graphic graphic_table graphicRef78084 \" href=\"mobipreview.htm?9/5/9307\">",
"       table 3",
"      </a>",
"      ), special needs, sleep apnea, decreased gastrointestinal motility, or airway abnormalities warrant consultation with a pediatric anesthesiologist or clinician with similar pediatric sedation expertise. (See",
"      <a class=\"local\" href=\"#H1683207\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic interventions, particularly distraction techniques, may relieve children's anxiety and pain distress before and during procedures and should be incorporated into pediatric procedural sedation whenever possible. (See",
"      <a class=\"local\" href=\"#H1684879\">",
"       'Nonpharmacologic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appropriate monitoring during pediatric sedation includes visual observation, initial and repeated measurements of vital signs, and continuous measurement of heart rate and pulse oximetry. We suggest that patients receiving moderate or deep procedural sedation also undergo monitoring with end-tidal CO2 detection throughout the procedure and during recovery when possible. (See",
"      <a class=\"local\" href=\"#H1683246\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Significant practice variation exists regarding the use of preoxygenation and continuous supplemental oxygenation during procedural sedation. If preoxygenation and continuous supplemental oxygen is provided, then the patient should also be monitored with continuous capnography or direct visualization of chest wall movement throughout sedation. (See",
"      <a class=\"local\" href=\"#H1683230\">",
"       'Preoxygenation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring should continue until the child meets criteria for safe discharge. The criteria are provided above. Young infants or children who are handicapped should return to the level of responsiveness observed before sedation. The exact duration of recovery time will vary with the nature of the patient (age, body mass index, etc) and the sedative agent or agents used (",
"      <a class=\"graphic graphic_table graphicRef83512 \" href=\"mobipreview.htm?32/0/32782\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83889 \" href=\"mobipreview.htm?30/28/31181\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Because of the significant risk of apnea after sedation, term infants with postconceptual ages (PCA) &le;45 weeks and former premature infants with PCA &lt;60 weeks should undergo prolonged observation of respiratory status prior to discharge. (See",
"      <a class=\"local\" href=\"#H1683339\">",
"       'Discharge criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In order to perform procedural sedation as safely as possible, institutions should develop protocols that specify a pre-sedation evaluation, including a sedation plan, monitoring during the procedure and recovery, discharge and follow-up criteria, credentialing for personnel, and a quality improvement monitoring mechanism. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Adverse outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/1\">",
"      Zempsky WT, Cravero JP, American Academy of Pediatrics Committee on Pediatric Emergency Medicine and Section on Anesthesiology and Pain Medicine. Relief of pain and anxiety in pediatric patients in emergency medical systems. Pediatrics 2004; 114:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/2\">",
"      Howard RF. Current status of pain management in children. JAMA 2003; 290:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/3\">",
"      Krauss B, Green SM. Procedural sedation and analgesia in children. Lancet 2006; 367:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/4\">",
"      Cravero JP, Blike GT. Review of pediatric sedation. Anesth Analg 2004; 99:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/5\">",
"      American Academy of Pediatrics, American Academy of Pediatric Dentistry, Cot&eacute; CJ, et al. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. Pediatrics 2006; 118:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/6\">",
"      Chen E, Joseph MH, Zeltzer LK. Behavioral and cognitive interventions in the treatment of pain in children. Pediatr Clin North Am 2000; 47:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/7\">",
"      Young KD. Pediatric procedural pain. Ann Emerg Med 2005; 45:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/8\">",
"      Cohen LL. Behavioral approaches to anxiety and pain management for pediatric venous access. Pediatrics 2008; 122 Suppl 3:S134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/9\">",
"      Cot&eacute; CJ. \"Conscious sedation\": time for this oxymoron to go away! J Pediatr 2001; 139:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/10\">",
"      Green SM, Krauss B. The semantics of ketamine. Ann Emerg Med 2000; 36:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/11\">",
"      Shavit I, Leder M, Cohen DM. Sedation provider practice variation: a survey analysis of pediatric emergency subspecialists and fellows. Pediatr Emerg Care 2010; 26:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/12\">",
"      Campbell IT, Beatty PC. Monitoring preoxygenation. Br J Anaesth 1994; 72:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/13\">",
"      HELLER ML, WATSON TR Jr, IMREDY DS. APNEIC OXYGENATION IN MAN: POLAROGRAPHIC ARTERIAL OXYGEN TENSION STUDY. Anesthesiology 1964; 25:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/14\">",
"      Fu ES, Downs JB, Schweiger JW, et al. Supplemental oxygen impairs detection of hypoventilation by pulse oximetry. Chest 2004; 126:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/15\">",
"      Green SM, Krauss B. Supplemental oxygen during propofol sedation: yes or no? Ann Emerg Med 2008; 52:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/16\">",
"      Lightdale JR, Goldmann DA, Feldman HA, et al. Microstream capnography improves patient monitoring during moderate sedation: a randomized, controlled trial. Pediatrics 2006; 117:e1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/17\">",
"      Burton JH, Harrah JD, Germann CA, Dillon DC. Does end-tidal carbon dioxide monitoring detect respiratory events prior to current sedation monitoring practices? Acad Emerg Med 2006; 13:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/18\">",
"      Miner JR, Heegaard W, Plummer D. End-tidal carbon dioxide monitoring during procedural sedation. Acad Emerg Med 2002; 9:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/19\">",
"      Malviya S, Voepel-Lewis T, Tait AR, et al. Effect of age and sedative agent on the accuracy of bispectral index in detecting depth of sedation in children. Pediatrics 2007; 120:e461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/20\">",
"      de Bie HM, Boersma M, Wattjes MP, et al. Preparing children with a mock scanner training protocol results in high quality structural and functional MRI scans. Eur J Pediatr 2010; 169:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/21\">",
"      French GM, Painter EC, Coury DL. Blowing away shot pain: a technique for pain management during immunization. Pediatrics 1994; 93:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/22\">",
"      Sinha M, Christopher NC, Fenn R, Reeves L. Evaluation of nonpharmacologic methods of pain and anxiety management for laceration repair in the pediatric emergency department. Pediatrics 2006; 117:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/23\">",
"      Duff AJ. Incorporating psychological approaches into routine paediatric venepuncture. Arch Dis Child 2003; 88:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/24\">",
"      American Academy of Pediatrics. Committee on Hospital Care. Child life services. Pediatrics 2000; 106:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/25\">",
"      Sury M, Bullock I, Rabar S, et al. Sedation for diagnostic and therapeutic procedures in children and young people: summary of NICE guidance. BMJ 2010; 341:c6819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/26\">",
"      Newman DH, Azer MM, Pitetti RD, Singh S. When is a patient safe for discharge after procedural sedation? The timing of adverse effect events in 1367 pediatric procedural sedations. Ann Emerg Med 2003; 42:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/27\">",
"      Walther-Larsen S, Rasmussen LS. The former preterm infant and risk of post-operative apnoea: recommendations for management. Acta Anaesthesiol Scand 2006; 50:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/28\">",
"      Cravero JP, Blike GT, Beach M, et al. Incidence and nature of adverse events during pediatric sedation/anesthesia for procedures outside the operating room: report from the Pediatric Sedation Research Consortium. Pediatrics 2006; 118:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/29\">",
"      Cot&eacute; CJ, Notterman DA, Karl HW, et al. Adverse sedation events in pediatrics: a critical incident analysis of contributing factors. Pediatrics 2000; 105:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/30\">",
"      Cot&eacute; CJ, Karl HW, Notterman DA, et al. Adverse sedation events in pediatrics: analysis of medications used for sedation. Pediatrics 2000; 106:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43384/abstract/31\">",
"      Pitetti R, Davis PJ, Redlinger R, et al. Effect on hospital-wide sedation practices after implementation of the 2001 JCAHO procedural sedation and analgesia guidelines. Arch Pediatr Adolesc Med 2006; 160:211.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6330 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43384=[""].join("\n");
var outline_f42_23_43384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GOALS OF SEDATION AND ANALGESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1683199\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1683207\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1683215\">",
"      PERFORMING PROCEDURAL SEDATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6090197\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1683014\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1683230\">",
"      Preoxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1683246\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1684879\">",
"      Nonpharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1535752\">",
"      Medication administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1683339\">",
"      DISCHARGE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      ADVERSE OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6330\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6330|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/0/32782\" title=\"table 1\">",
"      Intravenous agents for pediatric procedural sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/28/31181\" title=\"table 2\">",
"      Agents other than intravenous for pediatric sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/5/9307\" title=\"table 3\">",
"      ASA physical status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=related_link\">",
"      Awareness with recall following general anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31194?source=related_link\">",
"      Pharmacologic agents for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29432?source=related_link\">",
"      Preparation for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25658?source=related_link\">",
"      Selection of medications for pediatric procedural sedation outside of the operating room",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_23_43385="Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death";
var content_f42_23_43385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43385/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43385/contributors\">",
"     Jie Cheng, MD, PhD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43385/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43385/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43385/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/23/43385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/23/43385/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/23/43385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden cessation of cardiac activity with hemodynamic collapse, typically due to sustained ventricular",
"    <span class=\"nowrap\">",
"     tachycardia/ventricular",
"    </span>",
"    fibrillation. These events mostly occur in patients with structural heart disease (that may not have been previously diagnosed), particularly coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The event is referred to as SCA (or aborted SCD) if an intervention (eg, defibrillation) or spontaneous reversion restores circulation. The event is called SCD if the patient dies. However, the use of SCD to describe both fatal and nonfatal cardiac arrest persists by convention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/890?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among survivors of SCA, prevention of recurrent arrest is a central goal of long-term management. An implantable cardioverter-defibrillator (ICD) is the preferred approach for this purpose. Although the ICD does not prevent malignant ventricular arrhythmias, it treats them promptly when they occur.",
"   </p>",
"   <p>",
"    Issues related to use of the ICD in survivors of SCA will be reviewed here. Technical issues and complications associated with the ICD and the roles of pharmacologic therapy and other nonpharmacologic approaches (surgery and radiofrequency ablation) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the ICD in survivors of SCA was strongly suggested from a number of nonrandomized observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. These reports provided part of the rationale for the performance of randomized controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Major trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three major randomized trials, CASH, CIDS, and AVID, compared an ICD to pharmacologic therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , beta blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"     propafenone",
"    </a>",
"    in survivors of SCA or other high risk patients with sustained ventricular tachycardia (VT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of these trials are described in detail elsewhere. What follows are the findings from a meta-analysis and a summary of the largest trial, AVID. Because an ICD may shift the cause of death from sudden to non-sudden cardiac death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/7\">",
"     7",
"    </a>",
"    ], the most relevant outcome in these trials is not SCD, but total mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of these three trials and a fourth much smaller trial found a 25 percent reduction in mortality with an ICD compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (hazard ratio 0.75, 95 percent CI 0.64 to 0.87) that was entirely due to a 50 percent reduction in SCD (hazard ratio 0.50, 95% CI 0.34-0.62) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/12\">",
"       12",
"      </a>",
"      ]. The absolute reduction in all-cause mortality was 7 percent, meaning that approximately 15 patients needed to be treated to prevent one death.",
"     </li>",
"     <li>",
"      The AVID trial enrolled 1016 patients who had experienced either resuscitated SCA or symptomatic sustained VT (eg, syncope) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/11\">",
"       11",
"      </a>",
"      ]. In order to be enrolled, patients who qualified with symptomatic VT had to have an LVEF &le;40 percent. The trial was stopped early due to a survival benefit in patients receiving the ICD compared to those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_figure graphicRef82697 \" href=\"mobipreview.htm?20/54/21357\">",
"       figure 1",
"      </a>",
"      ). The major benefit of the ICD was the prevention of arrhythmic death (4.7 versus 10.8 percent with antiarrhythmic drugs, relative risk 0.44, 95% CI 0.28-0.70).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more complete discussion of the long-term outcome of survivors of SCD and the factors that affect prognosis is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30041?source=see_link&amp;anchor=H23#H23\">",
"     \"Outcome of sudden cardiac arrest\", section on 'Long-term outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanisms of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among SCA survivors, although ICD therapy improves survival, mortality remains high. The mechanisms of death in such patients were illustrated in analyses from CIDS, AVID, and other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonarrhythmic cardiac death, often progressive heart failure &ndash; 45 to 50 percent",
"     </li>",
"     <li>",
"      Arrhythmic death &ndash; 20 to 35 percent",
"     </li>",
"     <li>",
"      Noncardiac death, primarily renal and pulmonary disease in AVID &ndash; 20 to 30 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arrhythmic death can occur despite recognition and termination of tachyarrhythmias by the device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/16\">",
"     16",
"    </a>",
"    ]. These deaths often result from pulseless electrical activity (PEA), also called electromechanical dissociation or acute cardiac mechanical dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Support for this comes from an older study of 1729 patients seen between 1989 and 1993 who had an ICD that recorded and stored electrograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/14\">",
"     14",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      119 patients died during a six year follow-up; 83 of the deaths (70 percent) were cardiac, and 28 qualified as SCD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among the 83 patients who had a cardiac death, a stored electrogram within one hour of death was not present in 46 (55 percent), Because these devices store electrograms each time the recorded heart rate is above a programmed threshold, it was assumed that these deaths were not directly attributable to tachyarrhythmia.",
"     </li>",
"     <li>",
"      The 37 patients who did have stored electrograms within one hour of death all recorded tachyarrhythmias. The ICD failed to deliver a shock in 13 of these 33 patients, due to spontaneous slowing of the ventricular rate prior to shock delivery. Such a development preceding death suggests the progression from VF to an agonal rhythm, such as AIVR or PEA.",
"     </li>",
"     <li>",
"      Only seven of the 83 deaths (8.4 percent) were the immediate result of a tachyarrhythmia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further support for the role of electromechanical dissociation comes from a review of 320 patients who died after ICD implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/15\">",
"     15",
"    </a>",
"    ]. The mode of death was established by evaluating descriptions of the terminal event, clinical summaries, death certificates, and postmortem interrogation of the ICD memory logs. Among the 68 patients with SCD in whom a mechanism could be established, the cause was postshock electromechanical dissociation in 29 percent, primary electromechanical dissociation in 16 percent,",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    not terminated by the ICD in 25 percent, and",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    that recurred immediately after ICD termination in 13 percent. Postshock electromechanical dissociation was seen more commonly with high energy shocks in patients with advanced heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both a meta-analysis and the AVID trial found that the mortality benefit of an ICD compared to antiarrhythmic drug therapy was much more prominent in patients with a left ventricular ejection fraction (LVEF) &le;35 percent; there was little or no benefit when the LVEF was greater than 35 percent (",
"    <a class=\"graphic graphic_figure graphicRef67116 \" href=\"mobipreview.htm?27/34/28206\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Similar findings were noted in CIDS: benefit from an ICD was noted only in patients with at least two of the following three factors &mdash; age &ge;70, LVEF &le;35 percent, and NYHA class III or IV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    What is less clear is whether an ICD is beneficial in patients with an LVEF below 20 percent. In such patients, the mortality risk from progressive heart failure could mask any benefit from the ICD on arrhythmic mortality. Despite this theoretical concern, two observations suggest that the ICD may be beneficial in this setting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis from AVID, the subgroup of patients with an LVEF in this range had the same magnitude of survival benefit compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (72 versus 64 percent at two years) as those with an LVEF between 20 and 34 percent (83 versus 72 percent at two years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/18\">",
"       18",
"      </a>",
"      ]. However, the benefit in patients with an LVEF below 20 percent did not reach statistical significance, which may have been due to the relatively small number of patients.",
"     </li>",
"     <li>",
"      An earlier report evaluated 16 patients with a mean LVEF of 15 percent who were listed for heart transplantation and underwent ICD implantation for ventricular arrhythmias refractory to medical therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/20\">",
"       20",
"      </a>",
"      ]. The goal was to prevent a fatal arrhythmia while the patient waited for a suitable donor. The ICD delivered appropriate shocks for tachyarrhythmias associated with near syncope in all but one of the patients. Five patients of these patients had more than 10 shocks and three had five to nine shocks. Twelve patients underwent transplantation after a mean of 156 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These outcomes are much better than seen in similar patients not treated with an ICD. In a report of consecutive heart transplant candidates, the mortality rate was 4.7 percent in 21 patients treated with an ICD compared to 57 percent in 58 survivors of SCA treated medically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Transient or reversible disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been thought that patients with a life-threatening ventricular tachyarrhythmia due to a transient or reversible cause (most often an ischemic event) have a low risk for recurrent SCA after correction of the underlying problem. However, many such patients remain at high risk for SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. As an example, acute ischemic events occur in patients who may have had an antecedent MI or multivessel disease. The presence of scar from a prior MI and progression of CHD both increase the risk of future events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30041?source=see_link\">",
"     \"Outcome of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death included recommendations for the treatment of arrhythmias that occur in the setting of reversible causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The guidelines stated that evidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general opinion strongly support the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who experience cardiac arrest due to polymorphic VT or VF in the setting of acute ischemia or an MI should be treated with revascularization for the purpose of reducing the risk of SCD.",
"     </li>",
"     <li>",
"      In general, patients with polymorphic VT or VF who also have electrolyte disorders should be evaluated and treated in the same manner as other patients, unless the electrolyte abnormalities are proved to be the cause of the arrhythmia.",
"     </li>",
"     <li>",
"      Patients who experience sustained monomorphic VT in the setting of antiarrhythmic drug use or electrolyte abnormalities should be evaluated and treated in the same manner as other patients. Antiarrhythmic drugs or electrolyte abnormalities should not be assumed to be the sole cause of sustained monomorphic VT.",
"     </li>",
"     <li>",
"      Patients who experience polymorphic VT in the setting of acquired QT prolongation due to drug therapy should be advised to avoid exposure to all agents associated with QT prolongation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Causes of ICD discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of stored electrograms, it was not always clear why the ICD discharged. A discharge from the device was felt to be appropriate if there were symptoms suggesting arrhythmia preceding the discharge. There are, however, several problems with this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms might have been due to a supraventricular tachyarrhythmia, which could result in device discharge [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link&amp;anchor=H27332059#H27332059\">",
"       \"General principles of the implantable cardioverter-defibrillator\", section on 'Supraventricular tachyarrhythmias (including sinus tachycardia and atrial fibrillation) discrimination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient might have experienced a sustained arrhythmia that would not have been fatal or might have reverted spontaneously if not terminated by the device.",
"     </li>",
"     <li>",
"      Device discharge (shock or antitachycardia pacing) for a nonfatal arrhythmia may result in the precipitation of a serious rhythm abnormality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inappropriate discharges can also result from electromagnetic interference, lead fracture, and diaphragmatic myopotential sensing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link\">",
"       \"Implantable cardioverter-defibrillators: Complications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advent of devices that store retrievable electrograms of events that can be analyzed after an event have helped investigators more correctly quantify and characterize device discharges and to categorize whether shocks are delivered in response to spontaneous lethal arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/27,29-31\">",
"     27,29-31",
"    </a>",
"    ]. One report evaluated such data logging in 299 patients with a noncommitted ICD, which reconfirms the rhythm prior to shock delivery to avoid shocks for nonsustained VT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were noted after an average follow-up of 10 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were over 66,000 episodes of VT or VF in 281 patients (236 per patient). The arrhythmia terminated spontaneously in 74 percent, after antitachycardia pacing in 22 percent, and after a shock in only",
"      <strong>",
"       1.7 percent",
"      </strong>",
"      (four per patient).",
"     </li>",
"     <li>",
"      Inappropriate discharges, due to supraventricular tachyarrhythmia, electrical noise, or other cause, occurred in 92 patients (23 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with an ICD have a reduction in quality of life that is largely related to the occurrence of appropriate or inappropriate shocks from the ICD, fear of syncope or death, and restrictions on driving. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H25#H25\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Quality of life'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/20/30024?source=see_link\">",
"     \"Driving restrictions in patients with an implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Elderly patients and patients with comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the risks of noncardiac death, elderly patients and those with multiple or severe comorbidities may be less likely to derive benefit from an ICD. There is little direct evidence on the utility of ICD therapy for the secondary prevention of SCD in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/32\">",
"     32",
"    </a>",
"    ]. Results of a meta-analysis suggest that ICD therapy may not afford the same survival advantage over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    that is seen in younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/33\">",
"     33",
"    </a>",
"    ]. These results suggest that ICD use in elderly patients should be individualized. Patients without significant comorbidities may benefit, while those with significant other illnesses may be more likely to die of non-arrhythmic causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30599?source=see_link&amp;anchor=H8#H8\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\", section on 'Effect in elderly patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of an ICD in the primary prevention of SCD in the elderly is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link&amp;anchor=H7#H7\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'Impact of age and comorbidities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost-effectiveness of ICD implantation for secondary prevention is difficult to determine for several reasons. Variables to be considered include the cost of initial device implantation, the cost and frequency of generator change, the projected life expectancy and mortality rate of the population receiving the ICD, and the efficacy of ICD therapy. In addition, cost-effectiveness analysis often incorporates quality of life adjustments, which can be challenging due to the impact of device implantation, antiarrhythmic drugs, and concurrent diseases such as heart failure.",
"   </p>",
"   <p>",
"    Consistent with these uncertainties, estimates of cost-effectiveness have varied widely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/34-39\">",
"     34-39",
"    </a>",
"    ]. Initial assessments from retrospective and nonrandomized studies estimated that the ICD costs between $13,800 and $29,200 per year of life saved, which is within the range generally considered acceptable in the United States and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, higher costs were noted in an analysis on a subgroup of 237 patients in the AVID trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/37\">",
"     37",
"    </a>",
"    ]. Although ICD therapy resulted in a significant reduction in mortality, the increase in life expectancy at three years was modest (0.21 years greater than in patients treated with antiarrhythmic therapy). Thus, the cost-effectiveness of the ICD was relatively high, at $66,677 per year of life saved compared with drug therapy, which is in a range that is considered moderately cost-effective.",
"   </p>",
"   <p>",
"    An unfavorable cost-effectiveness ratio was found in the CIDS trial (Canadian $213,543 per life-year gained) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the CIDS trial was smaller than AVID and enrolled a more heterogeneous population with a lower overall mortality risk. These features would dilute the potential mortality benefit of ICD therapy and therefore detract from cost-effectiveness. Consistent with this hypothesis, among high-risk patients in CIDS (defined as having at least two of the following independent risk factors: age &ge;70, LVEF &le;35 percent, and NYHA class III or IV), the cost-effectiveness was similar to AVID (Canadian $65,195 per life-year gained) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further analysis has demonstrated that calculated ICD cost-effectiveness varies substantially with assumptions about ICD battery longevity and the quality of life effects of antiarrhythmic medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cost-effectiveness of ICD implantation has also been evaluated in primary prevention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=see_link&amp;anchor=H21#H21\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\", section on 'Cost-effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     UTILIZATION AND OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex and racial differences in ICD use for secondary prevention was found in an analysis of ICD use from 1999 to 2005 in a sample Medicare population with prior cardiac arrest or ventricular tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/40\">",
"     40",
"    </a>",
"    ]. ICD therapy was provided significantly less often to women than men (hazard ratio 0.41) and to black patients than white patients (HR 0.71). ICD therapy for secondary prevention was associated with reduced mortality in the subsequent year among men and women alive at 30 days after cohort entry (adjusted HR 0.66).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major potential antiarrhythmic adjunctive therapies in the patient with an ICD: antiarrhythmic drugs and catheter ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because an ICD does not prevent arrhythmias, patients who have frequent symptoms or device discharges from these arrhythmias may benefit from adjunctive antiarrhythmic drug therapy. In the two largest randomized trials comparing an ICD to pharmacologic therapy in survivors of SCA, an antiarrhythmic drug was added to ICD therapy in 22 percent at two years in AVID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/11\">",
"     11",
"    </a>",
"    ] and in 28 percent at five years in CIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of antiarrhythmic drugs in patients with an ICD is discussed in detail separately. Summarized briefly, there are three main indications for concomitant antiarrhythmic drug therapy, which most often consists of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    . Amiodarone is generally preferred and was shown in the OPTIC trial to be more effective than sotalol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To reduce the frequency of ventricular arrhythmia &ndash; in patients with frequent shocks delivered by the ICD which, in an analysis from AVID, was the primary reason for adding an antiarrhythmic drug (64 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/41\">",
"       41",
"      </a>",
"      ]. Patients with frequent shocks are more likely to become psychologically distressed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H25#H25\">",
"       \"Implantable cardioverter-defibrillators: Complications\", section on 'Quality of life'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To suppress other arrhythmias &ndash; Arrhythmias other than VT or VF may cause symptoms or interfere with ICD function, resulting in \"inappropriate\" discharges. These arrhythmias include sinus tachycardia, atrial arrhythmias, especially atrial fibrillation, and nonsustained VT (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Causes of ICD discharge'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      To reduce the rate of VT &ndash; VT may be better tolerated hemodynamically and more amenable to pace-termination or low energy cardioversion at lower rates. Although antiarrhythmic drugs may be used for these reasons, more sophisticated programming features may allow the device to ignore clinically unimportant and non-life-threatening arrhythmias rather than delivering an unnecessary shock.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While antiarrhythmic drugs are sometimes required to reduce the frequency of shocks and improve a person's quality of life, a systematic review of 17 studies involving nearly 6000 ICD recipients showed that shock prevention using antiarrhythmic therapy resulted in no improvement in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link&amp;anchor=H10#H10\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Systematic reviews'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to side effects, antiarrhythmic drugs may have an adverse effect on defibrillation thresholds and, by slowing the tachycardia rate, may preclude its recognition by the device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and particularly its major metabolite desethylamiodarone, increases the defibrillation threshold in a dose-dependent fashion; this effect is seen with monophasic and biphasic waveforms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These potential problems mandate reevaluation of defibrillation thresholds and tachycardia response whenever an antiarrhythmic drug is added, its dose changed, or a condition supervenes that is likely to alter the pharmacokinetics or pharmacodynamics of a drug in use. The NASPE guidelines for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy recommend that, whenever amiodarone is initiated in a patient with an ICD, a noninvasive ICD evaluation or an electrophysiology study should be performed to test for adverse drug-device interactions once loading is complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=see_link&amp;anchor=H6#H6\">",
"     \"Major side effects of amiodarone\", section on 'Cardiac toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers confer an additional survival benefit in patients with a myocardial infarction (MI), heart failure, or congenital long QT syndrome. Among survivors of SCA in the AVID trial, subset analysis found a significant improvement in survival with beta blocker therapy only in patients who did not receive specific antiarrhythmic therapy with an ICD or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lipid-lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients with coronary heart disease undergo aggressive lipid-lowering because of an improvement in overall survival and fewer recurrent coronary events. Among such patients who are survivors of SCA and have an ICD, lipid-lowering may reduce the rate of recurrent ventricular tachyarrhythmia (unstable ventricular tachycardia or ventricular fibrillation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link&amp;anchor=H2100326#H2100326\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Lipid-lowering'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To the degree that lipid-lowering does lower the rate of recurrent ventricular tachyarrhythmia, it should reduce symptoms such as syncope that may be associated with the arrhythmia and pain and anxiety related to appropriate ICD shocks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fish oil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies in low risk populations demonstrated an association between dietary fatty fish intake and lower cardiac mortality, due in part to a reduced risk of SCD. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=see_link&amp;anchor=H2#H2\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Fish oil and omega-3 fatty acids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these results, subsequent randomized trials evaluated the benefit of fish oil supplements in various high-risk populations. Three such trials of high dose fish oil supplementation (10 to 20 times higher than the nutritional dose in fish) have been performed in patients with an ICD and a history of sustained ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 200 patients with ICDs were randomly assigned to fish oil or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/53\">",
"       53",
"      </a>",
"      ]. There was no difference in mortality between the two groups, although fish oil therapy was associated with an increased frequency of ICD therapy in the subgroup of patients whose presenting arrhythmia was VT.",
"     </li>",
"     <li>",
"      The second trial included a similar but larger population of 402 patients with an ICD who were randomly assigned to fish oil or olive oil [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/54\">",
"       54",
"      </a>",
"      ]. At one year follow-up, patients treated with fish oil had a nonsignificant increase in the time to a first",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      event, but there was no difference in overall mortality or SCD in the two groups.",
"     </li>",
"     <li>",
"      A lack of clinically significant benefit was also noted in the SOFA trial, which randomly assigned 546 patients with an ICD to 2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      of fish oil versus placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/55\">",
"       55",
"      </a>",
"      ]. At a median follow-up of one year, there was no difference in the primary combined end point of appropriate ICD therapy for",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      and all-cause mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in ICD patients with a history of sustained ventricular arrhythmias, even high dose fish oil supplementation does not reduce mortality, and the effect on the frequency of ICD shocks is unclear. Interpretation of these trials is limited by relatively small sample sizes and high rates of noncompliance (up to 35 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to antiarrhythmic drug therapy in patients with frequent ICD shocks due to recurrent VT is RF ablation. Initial studies suggest that this approach can lead to a marked reduction in VT recurrences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=see_link&amp;anchor=H9#H9\">",
"     \"Catheter ablation for ventricular arrhythmias\", section on 'Adjunct to ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;We proceed with ICD implantation in most survivors of SCA. There is a limited role for antiarrhythmic medications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    catheter ablation as alternative or adjunctive therapies. In addition, there are rare exceptions to the recommendation of ICD therapy. The following recommendations are in broad agreement with guidelines published by American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    in 2006 and the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/24,56\">",
"     24,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     ICD therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, meta-analysis of the major randomized trials of survivors of SCA revealed a significant survival benefit with an ICD compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or other antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/12,17\">",
"     12,17",
"    </a>",
"    ]. The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities state that evidence and general opinion strongly support ICD use in most survivors of SCA that is not due to a transient or reversible cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/23/43385/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of ICDs in SCA survivors have been questioned in patients with both normal and very low LVEFs. The above randomized trials and meta-analysis demonstrated a benefit only in patients with an LVEF &le;35 percent. In contrast, SCA survivors with an LVEF &gt;40 percent have a better prognosis, while those with very poor systolic function (eg, LVEF &lt;20 percent) have elevated risks of nonarrhythmic death due to heart failure that may attenuate the benefit of an ICD. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Left ventricular dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Despite these concerns, the guidelines did not stratify their recommendations based upon the LVEF. This seems appropriate for two reasons: the prognostic importance of the LVEF was based upon subset analysis; and, given the current ease of ICD implantation, the consequences of choosing a possibly less effective therapy are too great. Furthermore, among patients with very poor systolic function, advances in the therapy of heart failure have improved survival, in part due to a lower rate of nonarrhythmic death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Reversible causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, ICD therapy for the purpose of secondary prevention was generally considered unnecessary if a ventricular arrhythmia occurred in the presence of a reversible cause (eg, ischemia or an electrolyte abnormality). However, it is not clear that such patients are at lower risk of recurrent ventricular arrhythmias and SCA. A thorough evaluation, usually involving an arrhythmia specialist, should be completed before concluding that SCA was due to a reversible cause. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Transient or reversible disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Correction of a reversible disorder is most likely to be adequate in two settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polymorphic VT or VF that is preceded by clear evidence of myocardial ischemia or acute myocardial infarction. In such cases, revascularization may be adequate for the purpose of reducing the risk of SCD. However, some of these patients will qualify for an ICD on the basis of primary prevention due to severe systolic dysfunction (MADIT II criteria) or systolic dysfunction and heart failure (SCD-HeFT criteria). Follow-up care with an arrhythmia specialist early after discharge should be arranged for additional risk stratification. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=see_link\">",
"       \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polymorphic VT in the setting of acquired QT prolongation. In such cases, withdrawal of the offending drug and avoidance of other QT prolonging medications may be adequate to reduce the risk of SCD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"       \"Acquired long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most other cases, life-threatening ventricular arrhythmias should not be attributed solely to a reversible disorder and patients should be evaluated according to standard approaches to secondary prevention. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Transient or reversible disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Exceptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few major exceptions to the preference for ICD therapy in survivors of SCA. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient refusal or severe comorbidities.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      occurring during or within 48 hours of an acute MI. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Reversible causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wolff-Parkinson-White syndrome, in which radiofrequency catheter ablation of the accessory pathway may be sufficient to prevent triggering of VF by rapid conduction over the accessory pathway during episodes of atrial fibrillation.",
"     </li>",
"     <li>",
"      Fulminant myocarditis in which a left ventricular assist device may be used as a bridge to spontaneous recovery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10874?source=see_link\">",
"       \"Natural history and therapy of myocarditis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced arrhythmias and severe electrolyte abnormalities, although SCA due to electrolyte abnormalities alone are rare, and care should be taken to avoid ascribing a malignant arrhythmia to an innocent or secondary electrolyte abnormality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adjunctive or alternative therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiarrhythmic drugs or catheter ablation can be considered in two main settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjunctive therapy in patients with an ICD, particularly in those with frequent shocks.",
"     </li>",
"     <li>",
"      As primary therapy in patients who do not want or are not candidates for an ICD (eg, due to marked comorbidities).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The defibrillation thresholds and tachycardia response of the ICD must be reevaluated whenever an antiarrhythmic drug that is known to increase the threshold, most noticeably",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , is added, its dose changed, or a condition supervenes that is likely to alter the pharmacokinetics or pharmacodynamics of a drug in use. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Adjunctive therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/60/38850?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204520\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among survivors of SCA, prevention of recurrent arrest is a central goal of long-term management. An implantable cardioverter-defibrillator (ICD) is the preferred approach for this purpose. Although the ICD does not prevent malignant ventricular arrhythmias, it treats them promptly when they occur. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three major randomized trials, CASH, CIDS, and AVID, compared an ICD to pharmacologic therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , beta blockers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      in survivors of SCA or other high-risk patients with sustained ventricular tachycardia (VT). A meta-analysis of these three trials and a fourth much smaller trial found a 25 percent reduction in mortality with an ICD compared to amiodarone that was entirely due to a 50 percent reduction in SCD. The absolute reduction in all-cause mortality was 7 percent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Major trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two major potential antiarrhythmic adjunctive therapies in the patient with an ICD: antiarrhythmic drugs and catheter ablation. Because an ICD does not prevent arrhythmias, patients who have frequent symptoms or device discharges from these arrhythmias may benefit from adjunctive antiarrhythmic drug therapy. There are three main indications for concomitant antiarrhythmic drug therapy, most often with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      : to reduce the frequency of VT, to suppress other arrhythmias, and to reduce the rate of VT. An alternative approach, radiofrequency catheter ablation, is presented in detail elsewhere. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Antiarrhythmic drugs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=see_link&amp;anchor=H9#H9\">",
"       \"Catheter ablation for ventricular arrhythmias\", section on 'Adjunct to ICD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We proceed with ICD implantation in most survivors of SCA. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/1\">",
"      Fogoros RN, Fiedler SB, Elson JJ. The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias. Ann Intern Med 1987; 107:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/2\">",
"      Winkle RA, Mead RH, Ruder MA, et al. Long-term outcome with the automatic implantable cardioverter-defibrillator. J Am Coll Cardiol 1989; 13:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/3\">",
"      Tchou PJ, Kadri N, Anderson J, et al. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med 1988; 109:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/4\">",
"      Fogoros RN, Elson JJ, Bonnet CA, et al. Long-term outcome of survivors of cardiac arrest whose therapy is guided by electrophysiologic testing. J Am Coll Cardiol 1992; 19:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/5\">",
"      Fogoros RN, Elson JJ, Bonnet CA, et al. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol 1990; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/6\">",
"      de Marchena E, Chakko S, Fernandez P, et al. Usefulness of the automatic implantable cardioverter defibrillator in improving survival of patients with severely depressed left ventricular function associated with coronary artery disease. Am J Cardiol 1991; 67:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/7\">",
"      Crandall BG, Morris CD, Cutler JE, et al. Implantable cardioverter-defibrillator therapy in survivors of out-of-hospital sudden cardiac death without inducible arrhythmias. J Am Coll Cardiol 1993; 21:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/8\">",
"      Newman D, Sauve MJ, Herre J, et al. Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992; 69:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/9\">",
"      Kuck KH, Cappato R, Siebels J, R&uuml;ppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/10\">",
"      Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/11\">",
"      A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/12\">",
"      Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 2003; 41:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/13\">",
"      Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol 1999; 34:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/14\">",
"      Grubman EM, Pavri BB, Shipman T, et al. Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators. J Am Coll Cardiol 1998; 32:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/15\">",
"      Mitchell LB, Pineda EA, Titus JL, et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol 2002; 39:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/16\">",
"      Pires LA, Lehmann MH, Steinman RT, et al. Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses. J Am Coll Cardiol 1999; 33:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/17\">",
"      Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/18\">",
"      Domanski MJ, Sakseena S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol 1999; 34:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/19\">",
"      Sheldon R, Connolly S, Krahn A, et al. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation 2000; 101:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/20\">",
"      Jeevanandam V, Bielefeld MR, Auteri JS, et al. The implantable defibrillator: an electronic bridge to cardiac transplantation. Circulation 1992; 86:II276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/21\">",
"      Grimm M, Wieselthaler G, Avanessian R, et al. The impact of implantable cardioverter-defibrillators on mortality among patients on the waiting list for heart transplantation. J Thorac Cardiovasc Surg 1995; 110:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/22\">",
"      Wyse DG, Friedman PL, Brodsky MA, et al. Life-threatening ventricular arrhythmias due to transient or correctable causes: high risk for death in follow-up. J Am Coll Cardiol 2001; 38:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/23\">",
"      Viskin S, Halkin A, Olgin JE. Treatable causes of sudden death: not really \"treatable\" or not really the cause? J Am Coll Cardiol 2001; 38:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/24\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/25\">",
"      Grimm W, Flores BF, Marchlinski FE. Electrocardiographically documented unnecessary, spontaneous shocks in 241 patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1992; 15:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/26\">",
"      Nanthakumar K, Paquette M, Newman D, et al. Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators. Am Heart J 2000; 139:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/27\">",
"      Wood MA, Stambler BS, Damiano RJ, et al. Lessons learned from data logging in a multicenter clinical trial using a late-generation implantable cardioverter-defibrillator. The Guardian ATP 4210 Multicenter Investigators Group. J Am Coll Cardiol 1994; 24:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/28\">",
"      Pinski SL, Fahy GJ. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation 1995; 92:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/29\">",
"      Hurwitz JL, Hook BG, Flores BT, Marchlinski FE. Importance of abortive shock capability with electrogram storage in cardioverter-defibrillator devices. J Am Coll Cardiol 1993; 21:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/30\">",
"      Wietholt D, Block M, Isbruch F, et al. Clinical experience with antitachycardia pacing and improved detection algorithms in a new implantable cardioverter-defibrillator. J Am Coll Cardiol 1993; 21:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/31\">",
"      Grimm W, Flores BF, Marchlinski FE. Symptoms and electrocardiographically documented rhythm preceding spontaneous shocks in patients with implantable cardioverter-defibrillator. Am J Cardiol 1993; 71:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/32\">",
"      Traub D, Ganz L. Implantable cardioverter-defibrillators for secondary prevention: is it worth it in the elderly? Am J Geriatr Cardiol 2006; 15:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/33\">",
"      Healey JS, Hallstrom AP, Kuck KH, et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J 2007; 28:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/34\">",
"      Kuppermann M, Luce BR, McGovern B, et al. An analysis of the cost effectiveness of the implantable defibrillator. Circulation 1990; 81:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/35\">",
"      O'Donoghue S, Platia EV, Brooks-Robinson S, Mispireta L. Automatic implantable cardioverter-defibrillator: is early implantation cost-effective? J Am Coll Cardiol 1990; 16:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/36\">",
"      Larsen GC, Manolis AS, Sonnenberg FA, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol 1992; 19:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/37\">",
"      Larsen G, Hallstrom A, McAnulty J, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 2002; 105:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/38\">",
"      O'Brien BJ, Connolly SJ, Goeree R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001; 103:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/39\">",
"      Sheldon R, O'Brien BJ, Blackhouse G, et al. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation 2001; 104:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/40\">",
"      Curtis LH, Al-Khatib SM, Shea AM, et al. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 2007; 298:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/41\">",
"      Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 2001; 142:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/42\">",
"      Ha AH, Ham I, Nair GM, et al. Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm 2012; 9:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/43\">",
"      Page RL. Effects of antiarrhythmic medication on implantable cardioverter-defibrillator function. Am J Cardiol 2000; 85:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/44\">",
"      Mann DE, Kelly PA, Damle RS, Reiter MJ. Undersensing during ventricular tachyarrhythmias in a third-generation implantable cardioverter defibrillator: diagnosis using stored electrograms and correction with programming. Pacing Clin Electrophysiol 1994; 17:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/45\">",
"      Goldschlager N, Epstein A, Friedman P, et al. Environmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators: a practical guide to patient treatment. Arch Intern Med 2001; 161:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/46\">",
"      Zhou L, Chen BP, Kluger J, et al. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998; 31:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/47\">",
"      Pelosi F Jr, Oral H, Kim MH, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000; 11:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/48\">",
"      Nielsen TD, Hamdan MH, Kowal RC, et al. Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. Am J Cardiol 2001; 88:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/49\">",
"      Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000; 160:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/50\">",
"      Exner DV, Reiffel JA, Epstein AE, et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 1999; 34:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/51\">",
"      Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003; 42:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/52\">",
"      De Sutter J, Tavernier R, De Buyzere M, et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000; 36:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/53\">",
"      Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005; 293:2884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/54\">",
"      Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005; 112:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/55\">",
"      Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006; 295:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/23/43385/abstract/56\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1017 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-30319E2B35-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43385=[""].join("\n");
var outline_f42_23_43385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H204520\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Major trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanisms of death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Transient or reversible disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Causes of ICD discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Elderly patients and patients with comorbidities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COST-EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      UTILIZATION AND OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADJUNCTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lipid-lowering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fish oil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ICD therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Reversible causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Exceptions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adjunctive or alternative therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204520\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1017\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1017|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/54/21357\" title=\"figure 1\">",
"      ICD versus antiarrhythmic drug AVID trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/34/28206\" title=\"figure 2\">",
"      Meta analysis ICD v amiodarone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/20/30024?source=related_link\">",
"      Driving restrictions in patients with an implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10874?source=related_link\">",
"      Natural history and therapy of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30041?source=related_link\">",
"      Outcome of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_23_43386="Porokeratosis of Mibelli";
var content_f42_23_43386=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81011%7EDERM%2F74020%7EDERM%2F81874%7EDERM%2F62258%7EDERM%2F73545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81011%7EDERM%2F74020%7EDERM%2F81874%7EDERM%2F62258%7EDERM%2F73545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Porokeratosis of Mibelli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large plaque with a slightly atrophic center and a prominent peripheral keratotic ridge is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disseminated superficial actinic porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple well-defined, erythematous macules with a peripheral rim of scale are present on the leg of this patient with disseminated superficial actinic porokeratosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disseminated superficial actinic porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, well-defined macules with a peripheral rim of scale are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear erythematous plaques with prominent keratotic rims are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43386=[""].join("\n");
var outline_f42_23_43386=null;
var title_f42_23_43387="Etiology of arrhythmias in congenital heart disease";
var content_f42_23_43387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of arrhythmias in congenital heart disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bradycardia",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital sinus node dysfunction",
"       </td>",
"       <td>",
"        Situs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital AV block",
"       </td>",
"       <td>",
"        AV canal defects; cc-TGA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acquired sinus node dysfunction",
"       </td>",
"       <td>",
"        s/p repair of Mustand/Senning, Fontan, Glenn or sinus venosus ASD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acquired AV node dysfunction",
"       </td>",
"       <td>",
"        s/p VSD/LVOT/aortic valve operation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tachycardia",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Twin AV nodes",
"       </td>",
"       <td>",
"        Heterotaxy syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial tachycardia/flutter",
"       </td>",
"       <td>",
"        Atrial baffles; post-MAZE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrial fibrillation",
"       </td>",
"       <td>",
"        ASD's, mitral valve disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ectopic atrial tachycardia",
"       </td>",
"       <td>",
"        Fontan",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AV: atrioventricular; cc-TGA: congenitally corrected transposition of the great arteries; ASD: atrial septal defect; VSD: ventricular septal defect; LVOT: left ventricular outflow tract.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43387=[""].join("\n");
var outline_f42_23_43387=null;
var title_f42_23_43388="Criteria for protein-energy wasting";
var content_f42_23_43388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for diagnosis of kidney disease-related protein-energy wasting",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Serum chemistry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum albumin &lt;3.8 g/dL (bromcresol green)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum prealbumin (transthyretin) &lt;30 mg/dL (for maintenance dialysis patients only; levels may vary according to glomerular filtration rate level for patients on CKD stages 2-5)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum cholesterol &lt;100 mg/dL*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Body mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        BMI &lt;23 kg/m",
"        <sup>",
"         2",
"        </sup>",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unintentional weight loss over time: 5 percent over 3 months or 10 percent over 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total body fat percentage &lt;10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Muscle mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Muscle wasting: reduced muscle mass 5 percent over 3 months or 10 percent over 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reduced mid-arm muscle circumference area",
"        <sup>",
"         &Delta;",
"        </sup>",
"        (reduction &gt;10 percent in relation to 50th percentile of reference population)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Creatinine appearance",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Dietary intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unintentional low-dietary protein intake &lt;0.80 g/kg/day for at least 2 months",
"        <sup>",
"         &sect;",
"        </sup>",
"        for dialysis patients or &lt;0.6 g/kg/day for patients on CKD stages 2-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unintentional low-dietary energy intake &lt;25 kcal/kg/day for at least 2 months",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    At least three out of the four listed categories (and at least one test in each of the selected categories) must be satisfied for the diagnosis of kidney disease-related PEW. Optimally, each criterion should be documented on at least three occasions, preferably two to three weeks apart.",
"    <div class=\"footnotes\">",
"     BMI: body mass index.",
"     <br>",
"      * Not valid if low concentrations are due to abnormally great urinary or gastrointestinal protein losses, to liver disease, or to cholesterol-lowering medicines.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       A lower BMI might be desirable for certain Asian populations; weight must be edema-free mass, for example, postdialysis dry weight. See text for the discussion about the BMI of the healthy population.",
"       <br>",
"        &Delta; Measurement must be performed by a trained anthropometrist.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Creatinine appearance is influenced by both muscle mass and meat intake.",
"         <br>",
"          &sect; Can be assessed by dietary diaries and interviews, or for protein intake by calculation of normalized protein equivalent of total nitrogen appearance (normalized protein nitrogen appearance or normalized protein catabolid rate) as determined by urea kinetic measurements.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Fouque D, Pelletier S, Mafra D, Chauveau P. Nutrition and chronic kidney disease. Kidney Int 2011; 80:348. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43388=[""].join("\n");
var outline_f42_23_43388=null;
var title_f42_23_43389="Cisplatin 80 plus etoposide for small cell lung cancer";
var content_f42_23_43389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cisplatin (80 mg/m",
"    <sup>",
"     2",
"    </sup>",
"    ) plus etoposide for small cell lung cancer",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: Every 21 days for four cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        80 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS) and administer over 60 minutes. Do not administer with aluminum needles or sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Etoposide",
"        </strong>",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV daily",
"       </td>",
"       <td>",
"        Dilute in 500 mL NS* or 5 percent dextrose in water (D5W) to final concentration &lt;0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur.",
"       </td>",
"       <td>",
"        Days 1, 2, and 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Routine prophylaxis not indicated. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of neutropenic fever is 8 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial",
"        <sup>",
"         [1]",
"        </sup>",
"        . A lower starting dose of etoposide may be needed for patients with renal or liver impairment",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Basic metabolic panel (creatinine and electrolytes) and liver function tests prior to each cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        A dose reduction of 25 percent for both etoposide and cisplatin is recommended for grade 4 neutropenia, febrile neutropenia, or grade 4 thrombocytopenia in the prior cycle",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Nephrotoxicity:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other severe non-hematologic toxicity:",
"        </strong>",
"        Etoposide and cisplatin should be withheld or doses decreased depending on clinical judgement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Lara PN, et al. J Clin Oncol 2009; 27:2530.",
"      </li>",
"      <li>",
"       Takada M, et al. J Clin Oncol 2002; 20:3054.",
"      </li>",
"      <li>",
"       Toposar (etoposide) injection. FDA-approved package insert US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed December 8, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43389=[""].join("\n");
var outline_f42_23_43389=null;
var title_f42_23_43390="Gram stain urine 2 with answer";
var content_f42_23_43390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enterococcus in urine: Gram stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of unspun urine (x1000) shows inflammatory cells and Gram positive cocci in chains. Enterococcus faecalis grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43390=[""].join("\n");
var outline_f42_23_43390=null;
var title_f42_23_43391="Endobronchial lesion of Kaposi sarcoma";
var content_f42_23_43391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F87393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F87393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endobronchial lesion of Kaposi sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous plaques of Kaposi sarcoma seen on bronchoscopy just proximal to the main carina in a patient who presented with an upper gastrointestinal bleed, gastric mucosal and skin lesions of Kaposi sarcoma, and a hemorrhagic pleural effusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_23_43391=[""].join("\n");
var outline_f42_23_43391=null;
              